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Abbreviations 
AUC Area under the curve 
BC Bladder cancer 
BS-SNaPshot Bisulfite specific single nucleotide primer extension 
CGI CpG island 
CIMP CpG island methylator phenotype 
CIS Carcinoma in situ 
CpG Cytosine phosphate Guanine 
DAC Decitabine 
DMH Differential methylation hybridization 
DNMT DNA methyltransferase 
EAU European association of urology 
EORTC European Organisation for Research and Treatment of 
Cancer 
GGMA Golden gate methylation assay 
GWS Genome-wide study 
HDAC Histone deacetylase 
LOOCV Leave one out cross-validation 
MIBC Muscle-invasive bladder cancer 
NMIBC  Non-muscle invasive bladder cancer 
NPV Negative predictive value 
PCA Principal component analysis 
PcG Polycomb group 
PPV Positive predictive value 
PreTUR Before trans-urethral resection 
ROC Receiver operating characteristic curve 
TSA Trichostatin 
TUR Trans-urethral resection 
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Introduction and scope of the thesis 
1.1 Bladder cancer: clinical characteristics 
Bladder cancer (BC) is the fth most common cancer in the western world after prostate, 
breast, lung and colorectal cancer with an estimated 386,300 new cases and 150,200 
deaths in the year 2008 worldwide. The majority of bladder cancers occur in men, with a 
male: female ratio of 3:1 [1]. The incidence is about 20 new cases per year per 100,000 
people in the U.S [1]. BC has been associated with exposure to a number of environmental 
factors. Smoking is the most important risk factor associated with bladder cancer [2]. Other 
risk factors are contact with heterocyclic amines in several industrial settings such as 
rubber manufacturing, petrochemical industry, dyestus and textile printing [3]. The most 
common symptom of bladder cancer is the development of haematuria (blood in the 
urine). This may be either macroscopic (visible to the eye) or microscopic (only detected by 
laboratory testing). Other symptoms include more frequent urination, dysuria (pain or 
burning sensation) and urgency. These symptoms do not always indicate bladder cancer. 
More often they are caused by infections, benign (non-cancerous) tumours, stones in the 
kidney or bladder, or other benign kidney diseases. If a bladder tumour is suspected 
cystoscopy (Figure 1) is performed, which is sometimes combined with cytology. More 
than 90% of BCs are urothelial cell carcinomas (UCCs). The other histological types 
encompass squamous cell carcinoma (6-8%) and adenocarcinoma (1-2%). In Egypt and 
other countries where endemic spread of schistosomiasis is more common, squamous cell 
carcinoma is the predominant subtype. The majority of UCC is found in the bladder. UCC of 
the renal pelvis, ureter and urethra accounts for less than 10% of the carcinomas.  
Most bladder tumours (70-80%) are non-muscle invasive BC (NMIBC) at the time of initial 
diagnosis and have a good prognosis [4]. NMIBC comprises stages pTa, pT1 and pTis 
(Figure 2). Unfortunately, 70% of the NMIBC cases will recur after transurethral resection 
(TUR), and 10-20% will eventually progress to muscle-invasive BC (MIBC) [5-7]. MIBC 
patients and those who progress to MIBC have a poor prognosis with a 5 years survival of 
10 to 50% depending on stage [8], in spite of radical cystectomy and chemotherapy. 
Somatic mutations in the FGFR3 gene accompanied by losses of chromosome 9 are more 
frequent in NMIBC, while TP53 mutations are associated with MIBC [9-11]. Based on the 
known genetic alterations a two pathway model for BC pathogenesis was described, which 
is depicted in Figure 3 [12, 13]. Besides these genetic aberrations, alterations in the 
epigenetic landscape like DNA methylation, histone modications and nucleosome 
remodeling are associated with bladder cancer [14, 15]. At this moment, BC treatment 
strategies and follow-up mostly depend on the Tumor, Node, Metastasis classication  
(TNM, Table 1) and grading proposed by the World Health Organization (WHO) in 1973 and 
2004 (Table 2) [16]. 
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Figure 2: Stage classication of bladder cancer. 
CIS: carcinoma in situ; Ta: Non-invasive 
papillary carcinoma; T1: Tumor invades 
connective tissue. T2: Tumor invades muscle. 
T3: Tumor invades fat layer. T4: Tumor invades 
other organs like prostate, uterus or vagina. 
CIS , Ta and T1 are NMIBC and T2, T3 and T4 are 
MIBC. Illustration by CancerHelp UK, the patient 
information website of Cancer Research UK: 
www.cancerhelp.ork.uk 
 
 
 
 
Figure 1: Diagram of a exible cystoscopy performed on 
a male patient. The lubricated cystoscope is passed 
through the urethra and lls the bladder with water. The 
lighted tip allows the surgeon to view the inner wall of 
the bladder. Illustration by Mayo Foundation for Medical 
Education and Research. 
Figure 3: Two-pathway model for disease pathogenesis of bladder cancer. Arrow thickness indicates the 
percentage of tumours. Chromosomal alterations are represented by the bottom arrow.11,13,14,21,38–43 
FGFR3, broblast growth factor receptor 3 gene; ↑, increased expression (MIB-1 and P53); ↓, reduced 
expression (P27kip1); CIS, carcinoma-in-situ. This gure is adapted from van Rhijn B W et al. JCO 003;21:1912-
1921 
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Table 1: 2009 TNM classi cation of urinary bladder 
cancer (from EAU guidelines) 
T Primary tumour 
TX  Primary tumour cannot be assessed  
T0  No evidence of primary tumour  
Ta  Noninvasive papillary carcinoma  
Tis  Carcinoma in situ: ‘ at tumour’  
T1  
Tumour invades subepithelial 
connective tissue  
T2  Tumour invades muscle  
T2a Tumour invades super cial 
muscle (inner half)  
T2b Tumour invades deep muscle 
(outer half)  
T3  Tumour invades perivesical tissue:  
T3a Microscopically  
T3b Macroscopically (extravesical 
mass)  
T4  
Tumour invades any of the following: 
prostate, uterus,  
vagina, pelvic wall, abdominal wall  
T4a Tumour invades prostate, uterus, 
or vagina  
T4b Tumour invades pelvic wall or 
abdominal wall  
N Lymph nodes 
NX  
Regional lymph nodes cannot be 
assessed  
N0  No regional lymph node metastasis  
N1  
Metastasis in a single lymph node in 
the true pelvis  
(hypogastric, obturator, external iliac, 
or presacral)  
N2  
Metastasis in multiple lymph nodes in 
the true pelvis  
(hypogastric, obturator, external iliac, 
or presacral)  
N3  
Metastasis in a common iliac lymph 
node(s)  
M Distant metastasis 
MX  
Distant metastasis cannot be 
assessed  
M0  No distant metastasis  
M1  Distant metastasis  
Table 2: World Health Organisation grading in 
1973 and in 2004; CIS = carcinoma in situ. (from 
EAU guidelines) 
1973 WHO grading  
Urothelial papilloma:  
Grade 1: well di erentiated  
Grade 2: moderately di erentiated  
Grade 3: poorly di erentiated  
2004 WHO grading  
Flat lesions:  
Hyperplasia ( at lesion without atypia or 
papillary)  
Reactive atypia ( at lesion with atypia)  
Atypia of unknown signi cance  
Urothelial dysplasia  
Urothelial CIS  
Papillary lesions:  
Urothelial papilloma (which is a completely 
benign lesion)  
Papillary urothelial neoplasm of low malignant 
potential  
Low-grade papillary urothelial carcinoma  
High-grade papillary urothelial carcinoma  
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NMIBC is treated by transurethral resection (TUR), followed by one cycle of chemotherapy. 
High grade (G3) and T1 tumours are further treated with bacillus Calmette Guérin (BCG) 
instillations to delay recurrence and to prevent progression. MIBC is treated with 
cystectomy, radiation or chemotherapy to reduce the disease-specific mortality.  
In principle, the three major risks for patients with NMIBC after initial treatment include 
tumor recurrence, progression to a higher grade or stage, and for MIBC death due to 
metastatic disease. Conventional clinical and pathologic parameters are widely used to 
grade and stage tumors in order to predict clinical outcome of BC. For NMIBC risk scores 
for recurrence and progression have been developed by Sylvester [17] and these have 
been taken up in the EAU guidelines [18]. (Table 3 and 4). However, these risk scores were 
based on a cohort of patient from the nineteen eighties, a time when TUR was not 
followed by an initial installation of a chemotherapeutic drug such as mitomycin C and 
when treatment of patients with high risk NMIBC with BCG was not carried out yet. In 
addition, especially grading has been shown to be rather subjective with considerable 
interobserver variation [19]. Molecular markers such as the specific point mutations in the 
FGFR3 gene that occur in over 75% of stage Ta tumours have been associated with a 
relatively benign disease course [10]. Moreover, reproducibility of the FGFR3 mutation 
assay was shown to be 100%.  Besides the FGFR3 mutations other molecular markers with 
similar performance would be very welcome to better predict disease course in NMI as well 
as in MIBC.   
Cystoscopy is the gold standard for surveillance of patients with a previous bladder 
tumour, however, it is an invasive and uncomfortable procedure [20, 21]. Moreover, even 
with cystoscopy, there is 20 to 30% chance to miss a tumour [22, 23]. Due to the high 
recurrence rate, depending on the risk group of the patient, NMIBC patients are monitored 
by cystoscopy every 3-12 months after TUR in order to spot potential recurrences. This 
sums to an average of about 20 cystoscopies per patient in the first decade following 
removal of the primary tumour, thus making BC one of the most expensive cancers to treat 
[24]. Cytological examination of voided urine can identify tumour cells with a high 
sensitivity if a high-grade tumour is present [25]. However, for low stage and grade 
tumours the sensitivity is low. This low sensitivity induced the development of urine-based 
assays in the past decade [8]. In summary, these assays are based on immunological assays 
to detect tumour cells, differentially expressed genes, tumour-associated proteins and 
tumour-specific DNA alterations [26-29]. Three of these tests have been approved by the 
FDA (Federal Drug Administration, USA), namely NMP22, UroVysion, and ImmunoCyt [25, 
30]. Although most tests have better sensitivity than urinary cytology, their specificity is 
lower and their sensitivity for low grade recurrent tumours is also insufficient. Hence, none 
of them have been accepted as a standard diagnostic procedure in routine urology to 
date.  The FGFR3 mutations test is an excellent diagnostic test for recurrent cancer in 
patients presenting with NMIBC if their primary tumour harbors a mutation. Evidently, 
other tests are required for those patients with FGFR3 wild-type tumours. 
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Table 3: Weighting used to calculate recurrence and progression scores. (from EAU guidelines) 
Factor Recurrence Progression 
No. of tumours  
Single 0 0 
2–7  3 3 
≥8 6 3 
Tumour diameter  
<3 cm  0 0 
≥3 cm 3 3 
Prior recurrence rate  
Primary 0 0 
≤1 recurrence per year 2 2 
>1 recurrence per year 4 2 
Category 
Ta 0 0 
T1  1 4 
Concomitant CIS  
No  0 0 
Yes  1 6 
Grade (1973 WHO) 
G1 0 0 
G2  1 0 
G3  2 5 
Total score  0–17  0–23  
Table 4: Probability of recurrence and progression according to total score. CI = confidence interval. (from 
EAU guidelines) 
Recurrence score 
Probability of recurrence 
at 1 yr 
Probability of recurrence 
at 5 yr 
Recurrence risk 
group 
% (95% CI) % (95% CI) 
0 15 (10–19) 31 (24–37) Low risk 
1–4 24 (21–26) 46 (42–39) Intermediate risk 
5–9 38 (35–41) 62 (58–65) Intermediate risk 
10–17 61 (55–67) 78 (73–84) High risk 
Progression score 
Probability of progression 
at 1 yr 
Probability of progression 
at 5 yr 
Progression risk 
group 
% (95% CI) % (95% CI) 
0 0.2 (0–0.7) 0.8 (0–1.7) Low risk 
2–6 1 (0.4–1.6) 6 (5–8) Intermediate risk 
7–13 5 (4–7) 17 (14–20) High risk 
14–23 17 (10–24) 45 (35–55) High risk 
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1.2 Epigenetics 
Conrad Waddington introduced the term epigenetics in the early 1940s [31]. Epigenetics 
refers to ‘‘the study of changes in gene function that are mitotically and/or meiotically 
heritable and that do not entail a change in DNA sequence’’ [32, 33]. At present, there are 
two major components of the epigenome, which are DNA methylation and histone 
modifications. A great variety of post-translational covalent histone modifications 
(acetylation, methylation, phosphorylation etc.) are associated with actively transcribed or 
inactive chromatin (Figure 4) [33]. DNA methylation is mediated by a family of enzymes 
termed DNA methyltransferases (DNMTs). The components of the epigenome together 
function in highly dynamic processes, responsible for activation or deactivation of gene 
expression throughout the life span of a cell. Alterations of the epigenetic landscape in a 
normal cell can lead to malignant transformation and cause cancer. The epigenetic 
progenitor model of cancer described by Feinberg [34] claims that cancer develops in 
three steps. The first being an epigenetic alteration of a stem or progenitor cell within a 
given tissue and the second a gate-keeper mutation followed by genetic and epigenetic 
instability leading to further tumour evolution. This hypothesis is supported by studies that 
showed that epigenetic alterations precede the initial mutations in cancer [35-37].  
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Figure 4: The two main components of the epigenetic code. DNA methylation and histone modications. This 
gure is adapted from Applied Biosystems. 
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1.3 DNA methylation 
DNA methylation is currently the most widely studied epigenetic aberration. DNA 
methylation is mediated by the cytosine DNA methyltransferase (DNMT) family of enzymes 
that catalyze the transfer of a methyl group from S-adenosyl methionine to cytosines, 
thereby creating a 5-methylcytosine (5 mC). This occurs only in the background of a 
cytosine (C) followed by a guanine (G) in the DNA. The CG dinucleotide is commonly 
known as CpG.  DNMT1 is primarily responsible for maintaining the methylation signature 
by copying the pre-existing methylation pattern onto the daughter strand after DNA 
replication. DNMT3A and DNMT3B are de novo enzymes that target previously 
unmethylated CpGs [38, 39]. DNMT1 is the most abundant DNMT in the cell [40, 41].  
DNA methylation is essential for normal development [42] and is associated with a number 
of key functions such as genomic imprinting [43], X-chromosome inactivation in females 
[44] and suppression of repetitive elements. CpG dinucleotides are not distributed 
uniformly throughout the human genome. Rather, they are most frequently found within 
dense CpG sequence stretches termed CpG islands, dened as “regions of more than 200 
bases with a G + C content of at least 50% and a ratio of observed to statistically expected 
CpG frequencies of at least 0.6” [45]. Although CpG islands (CGIs) constitute only 1% of the 
total genome, they are present in >50% of human gene promoters indicating their role in 
regulation of gene expression.  
DNA methylation of the promoter regions is generally associated with transcriptional 
repression through dierent mechanisms, including the inhibition of transcription factor 
binding and the recruitment of methyl-binding domain proteins (MBD1, MBD2 and 
MeCP2) and their associated complexes [46]. In normal cells, promoter CpG islands are 
usually unmethylated while the genome is globally methylated thereby preventing 
genome instability (Figure 5) [46].  
Figure 5: DNA methylation in normal and cancer cells. In normal cells, nearly all of the CpG dinucleotides are 
methylated whereas CpG islands, mostly residing in 5΄ regulatory regions of genes, are unmethylated. In 
cancer cells, many CpG islands become hypermethylated, in combination with silencing of their associated 
genes, while global hypomethylation, mostly at repetitive elements, occurs. 
Recently it is discovered that 5-mC can be converted into 5-hydroxymethylcytosine (5-
hmC) by the 2-oxoglutarate– and Fe(II)-dependent oxygenases TET1, TET2 and TET3 [47]. 
These modications have recently been detected in embryonic stem (ES) cells and Purkinje 
neurons and are shown to be involved in ES cell self-renewal and embryonic inner cell 
Exon Exon  Repeat
x
Cancer
Exon RepeatNormal Exon  
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mass specification.  Conversion of 5-mC to 5-hmC results in reactivation of gene expression 
[48].  
Cancers can be classified according to their degree of methylation, and those cancers with 
high degrees of methylation (CpG island methylator phenotype, or CIMP) represent a 
clinically and etiologically distinct group that is associated with ‘epigenetic instability’. This 
mechanism was first described in colorectal cancer, but later on confirmed in many 
different cancers namely glioblastomas, gastric cancer, liver cancer, pancreatic cancer, 
esophageal cancer, ovarian cancer, acute lymphocytic leukaemia and acute myelogenous 
leukaemia [39, 49]. PcG complexes repress gene transcription by altering histone 
modifications around the transcription start site of genes involved in lineage specification 
during development. The altered histones can attract DNMTs and this can result in 
aberrant DNA methylation and irreversible shut down of the genes in question. It has been 
established that PcG target genes are frequently aberrantly hypermethylated by DNA 
methylation in cancer [50-52]. These studies revealed that PcG target genes are as much as 
12 times more likely to be aberrantly silenced by DNA methylation in cancer than non-PcG 
target genes.  It is therefore thought that hypermethylation in cancer occurs early in the 
tumorigenic process and may already be present in some cells during development.  
1.4 Histone modifications 
Histone modifications influence chromatin structure which plays an important role in gene 
regulation and carcinogenesis [53]. Chromatin is a highly ordered structure consisting of 
repeats of nucleosomes connected by linker DNA. Each nucleosome encompasses 146 bp 
of DNA wrapped around an octamer of histone proteins. These octamers consist of two 
subunits of each of the following core histone proteins: H2A, H2B, H3 and H4 [54]. 
Chromatin consists of DNA, histones, and non-histone proteins condensed into 
nucleoprotein complexes and functions as the physiological template of all eukaryotic 
genetic information [55]. Histones are small basic proteins containing a globular domain 
and a flexible charged NH2 terminus known as the histone tail, which protrudes from the 
nucleosome. Regulation of gene expression occurs through posttranslational 
modifications of the histone tails provided by covalent modifications including acetylation, 
methylation, phosphorylation, ubiquitination, sumoylation, proline isomerization, and ADP 
ribosylation [56-58]. Posttranslational modifications regulate the structural status of 
chromatin and thereby transcriptional status of genes within a particular locus. These 
modifications are reversible and are controlled by a group of enzymes. The enzymes that 
add and remove such modifications are, respectively, histone acetyltransferases (HATs) 
and deacetylases (HDACs and sirtuins), methyltransferases (HMTs) and demethylases 
(HDMs), kinases and phosphatases, ubiquitin ligases and deubiquitinases, SUMO ligases 
and proteases [57, 58]. Chromatin is divided into two distinct conformation states: 
heterochromatin, which is densely compacted and transcriptionally inert and euchromatin, 
which is open and transcriptionally active. Euchromatin is characterized by high levels of 
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acetylation and trimethylated H3K4, H3K36 and H3K79. On the other hand, 
heterochromatin is characterized by low levels of acetylation and high levels of H3K9, 
H3K27 and H4K20 methylation [59-61]. Genome-wide studies have revealed that various 
combinations of histone modifications in a specific genomic region can lead to a more 
‘open’ or ‘closed’ chromatin structure resulting in the activation or repression of gene 
expression. For example, trimethylation of lysines (K) 4, 36 or 79 on H3 (H3K4me3, 
H3K36me3 and H3K79me3, respectively), monomethylation of H4K20 and H2BK5 
(H4K20me and H2BK5me), and acetylation of H3K9 and H3K14 (H3K9ac and H3K14ac) 
result in gene activation, whereas di or trimethylation of H3K9 (H3K9me2 and H3K9me3) 
and trimethylation of H3K27 (H3K27me3) lead to gene repression [60, 62, 63]. In embryonic 
stem cells, key developmental genes remain poised for lineage-specific activation or 
repression as a result of their bivalent domains, a combination of two modifications in their 
promoter regions, H3K4me3 for active and H3K27me3 for repressive marks [63]. 
1.5 DNA methylation as a biomarker and therapeutic target in 
cancer 
DNA methylation shows much promise as a potential biomarker for clinical application in 
cancer. DNA is the most stable biological macromolecule and DNA methylation being a 
covalent modification is a very stable bond. Unlike genetic mutations, which could occur 
anywhere in a gene, cancer-specific DNA hypermethylation occurs in defined regions, 
usually in or near the promoter of genes. DNA methylation affects long sequences of DNA 
rather than single nucleotides, allowing more efficient and robust assay designs. Promoter 
hypermethylation occurs frequently in human cancer and is an early event in cancer 
development making it an ideal candidate for early diagnosis, prognosis, predictive and 
therapeutic target [64, 65]. To be clinically useful, a tumour biomarker should be able to be 
detectable in clinical specimens through non-invasive procedures and DNA 
hypermethylation seems to fulfill this requirement. Because of the fact that these 
aberrations can also be detected in the exfoliated cells from voided urine, this gives a 
possibility for non-invasive detection of BC.  
Unlike genetic abnormalities, epigenetic modifications are to some extent reversible. 
Currently two major classes of epigenetic drugs have been developed and these are being 
used in clinical trials. The first class of epigenetic drugs involves histone deacetylase 
(HDAC) inhibitors, which targets histone acetylation. Histone acetylation leads to open 
chromatin helping gene expression, inhibition of deacetylation by HDACs will 
consequently induce gene expression. Presently, there are two FDA approved HDAC 
inhibitors: suberoylanilide hydroxamic acid (SAHA, Zolinza) and romidepsin (Istodax). The 
HDAC inhibitors SAHA and romidepsin are approved for the treatment of cutaneous T-cell 
lymphoma [66, 67]. Many other HDAC inhibitors are currently undergoing clinical testing 
for several cancers. The second class of epigenetic drugs are DNMT inhibitors, which are 
typically cytidine analogues: 5-azacytidine (Azacytidine) [68] and 5-azadeoxycytidine 
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(Decitabine) [69]. Cell division is required for the action of DNMT inhibitors as they 
compete with normal cytidine for incorporation into the DNA to function. Cytidine 
analogues are recognized by DNA methyltransferases as natural substrate and the 
enzymes will initiate the methylation reaction by binding to the DNA covalently, which 
blocks the DNA methyltransferase function. In addition, the covalent binding also 
compromises the functionality of DNA and triggers DNA damage signaling, resulting in the 
degradation of trapped DNA methyltransferases. As a consequence, methylation marks 
become lost during DNA replication [70]. 5-Azacytidine and decitabine have shown 
signicant clinical benet in the treatment of myelodysplastic syndrome [71, 72] and are 
also used for the treatment of myeloid leukemias. The use of these epigenetic drugs is still 
under investigation to treat solid tumours. Though these drugs have a tremendous 
potential in cancer treatment, their non-specicity and toxicity are the major limitations.  
1.6 Scope and outline of this thesis 
The identication of epigenetic aberrations in BC could clarify the pathogenesis of this 
disease, provide insight into the possible dierent epigenetic patterns, and eventually 
result in useful clinical tools. Chapter 1 gives a general background of BC and DNA 
methylation. The review in chapter 2 summarizes the DNA methylation biomarkers 
discovered in BC so far. The general scope of the thesis is to understand the pathogenesis 
of BC, detect molecular epigenetic biomarkers for diagnosis and surveillance in urine and 
prognosis of BC in various clinical settings.  
In chapter 3 we describe a genome-wide DNA methylation analysis on 44 bladder 
tumours using the Agilent 244K Human CpG Island Microarray. Validation of identied 
methylated CGIs was done using a custom Illumina 384-plex assay (Illumina, San Diego, 
CA, USA) in 77 independent tumours. This genome-wide investigation revealed distinct 
DNA methylation patterns in BC subtypes. Furthermore, extensive methylation indicative 
of a CpG island methylator phenotype was observed in FGFR3 wild-type NMI tumours. 
Most de novo methylated genes in bladder cancer were found to be known targets of 
repression by polycomb group proteins in embryonic stem cells. The genome-wide 
screening and subsequent validation allowed us to conrm 110 CGIs that signicantly 
diered in methylation in tumours when compared to urine-derived DNA from age-
matched non-BC controls. These CGIs represent potential biomarkers for urine tests (see 
below). Furthermore, four markers (TBX2, TBX3, GATA2 and ZIC4) for predicting progression 
were identied in pTa (n = 24) tumours and they were validated in an independent series 
of 41 pTa tumours by the SNaPshot method. We further found that the accuracy of 
predicting progression using the EAU risk scores as developed by Sylvester [73] is 
improved by 23% by adding methylation of TBX2, TBX3, and GATA2 to the model.  
We next decided to develop a diagnostic assay for the detection of recurrent bladder 
cancer in voided urine by using specic CGIs from the genome-wide study. This is 
described in chapter 4. To this end, we selected eight candidate CGIs methylated in 
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bladder cancer but not in urinary cells from healthy individuals. This was performed on a 
test and validation set of recurrence associated urines from 196 BC patients and 70 urines 
from age-matched non-bladder cancer controls.  We found a panel of three methylation 
markers in combination with the FGFR3 mutation assay detecting recurrent BC in voided 
urine with a sensitivity of 79% at a specicity of 90%. This is the rst study specically used 
recurrence associated urines from primary Ta G1/G2 tumours as it is important to note that 
the recurrent tumours are smaller than the primary tumours. As the earlier studies used a 
mixture of primary and recurrence associated urines, the sensitivity is high. 
Our genome-wide methylation study in bladder cancer revealed that DNA methylation in 
bladder tumours was equally distributed over both promoter and gene body CpG islands. 
Many previous studies had shown that promoter methylation leads to repression of gene 
expression, however, the eect of methylation of intragenenic CGIs was not known and is 
still being investigated. We decided to study the eect of gene body methylation in more 
detail and this is described in chapter 5. To identify the eect of intragenic methylation on 
gene silencing, we selected the 21 most hypermethylated genes in bladder cancer and 
studied the gene reactivation pattern by treating bladder cancer cell lines with the DNA 
demethylating agent decitabine and with decitabine in combination with the deacetylase 
inhibitor trichostatin A. In general we found that intragenic methylation could also lead to 
gene silencing, but further experiments are necessary to unravel the mechanism. Finally in 
chapter 6 we discuss the results described in this thesis along with suggestions for the 
future. 
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Abstract 
Context 
Urinary bladder cancer (BC) is the fifth most common cancer in the Western world. DNA 
methylation contributes to the pathogenesis of various cancers including BC, and may 
serve as a useful biomarker for diagnostic, prognostic, and predictive purposes.   
Objective 
In this systematic review, we investigated DNA methylation in BC, its relation to 
pathogenesis and its use as a diagnostic and/or prognostic marker.   
Evidence Acquisition 
A PubMed search was performed using MESH terms (Urinary Bladder Neoplasms and DNA 
Methylation) and general search terms (DNA methylation and Bladder cancer) until April 
2012. This yielded a total of 259 articles. The following articles were excluded: reviews, 
non-English articles and non-bladder cancer related articles. This reduced the number of 
articles to 86, which are discussed in this review. 
Evidence Synthesis 
Genome-wide methylation studies implicated several aspects of BC pathogenesis. 
Methylation of normal urothelium next to the tumour was observed, defined as epigenetic 
field defect. This suggests that methylation precedes tumorigenesis. Most methylated 
genes are found to be PcG targets. This again implies that methylation could be an early 
event. Furthermore, distinct methylation patterns were identified between non-muscle 
invasive (NMI) and muscle-invasive (MI) BC, as well as between FGFR3 mutant and wild 
type tumours. The profound methylation observed in FGFR3 wild type tumours could 
indicate the CpG island methylator phenotype (CIMP). Thus like the genetic alterations, 
epigenetic alterations also differ between subgroups of BC. These genome-wide studies 
together with small scale cancer specific gene studies have led to the identification of 
several tumour and urine biomarkers for the diagnosis, prognosis and prediction of BC.  
Conclusions 
Methylation of Myopodin, TBX2, TBX3, GATA2 and ZIC4 genes were shown to be associated 
with progression in NMIBC on two independent patient cohorts. Methylation of RASSF1A, 
CDH1, RUNX3 and TIMP3 were shown to be associated with progression in different 
studies. Methylation of CDH1, FHIT, LAMC2, RASSF1A, TIMP3, SFRP1, SOX9, PMF1, and RUNX3 
were shown to be associated with poor survival in MIBC in different studies. PMF1 gene 
methylation was identified to predict bacillus Calmette-Gue´rin (BCG) response in T1G3 BC. 
Several studies have identified sensitive urine biomarkers, but most used a mixture of 
primary and recurrent tumour associated urines. TWIST1 and NID2 genes have shown a 
good sensitivity in detecting primary tumours, while OTX1, ONECUT2 and OSR1 genes have 
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displayed a good sensitivity in detecting recurrent bladder tumours in voided urine. 
However, most of these studies were retrospective and therefore there is a need to 
perform large randomized prospective multicenter validation studies to prove which 
markers are valuable to bring into the clinic.  Further testing of urine biomarkers in a 
randomized control trial together with cystoscopy will reveal whether urine testing can 
replace or add to the cystoscopy. The markers which are identified to predict progression, 
survival and BCG response will help in clinical decision making and eventually for 
individualized treatment.  
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Introduction 
BC is the fifth most common cancer in the western world with an estimated 386,300 new 
cases and 150,200 deaths in the year 2008 worldwide [1]. Most bladder tumours (70-80%) 
present as non-muscle invasive (NMIBC) and have a good prognosis. Muscle-invasive BC 
(MIBC) and patients who progress to MIBC have a poor prognosis with a 5 year survival rate 
of 10-50% depending on stage and despite treatment [2]. NMIBC comprises stages pTa, 
pT1 and pTis. Unfortunately, 70% of the NMIBC cases will recur after transurethral resection 
(TUR) and 10-20% will eventually progress to muscle-invasive BC [3-5]. Genomic alterations 
like somatic mutations in the FGFR3 gene accompanied with losses of chromosome 9 are 
more frequent in NMIBC, while TP53 mutations are associated with MIBC [6-8]. Besides 
these genetic aberrations, alterations in the epigenetic landscape like DNA methylation, 
histone modifications, miRNAs and nucleosome remodeling are associated with bladder 
cancer pathogenesis [9, 10].  
Conrad Waddington introduced the term epigenetics in the early 1940s [11]. Epigenetics 
refers to ‘‘the study of changes in gene function that are mitotically and/or meiotically 
heritable and that do not entail a change in DNA sequence’’ [12, 13].  DNA methylation has 
been shown to contribute to the pathogenesis of various cancers including bladder cancer 
[14-17]. DNA hypermethylation is often found in CpG islands (CGIs) in the 5’ regions of 
genes overlapping promoter regions. DNA methylation is mediated by the cytosine DNA 
methyltransferase (DNMT) family of enzymes that catalyze the transfer of a methyl group 
from S-adenosyl methionine to DNA. DNMT1 is primarily responsible for maintaining the 
methylation signature by copying the pre-existing methylation pattern onto the daughter 
strand after DNA replication. DNMT3A and DNMT3B are de novo enzymes that target previ-
ously unmethylated CpGs [18, 19]. DNA methylation negatively effects gene expression 
and may contribute to cancer pathogenesis, and consequently DNA modifications may 
serve as useful biomarkers, both for diagnostic, prognostic and predictive purposes.  
At this moment, BC treatment strategies and follow-up mostly depend on the Tumor, 
Node, Metastasis classification (TNM) and grading proposed by the World Health 
Organization (WHO) in 1973 and 2004 [2]. NMIBC is treated by transurethral resection 
(TUR), followed by one cycle of chemotherapy. High grade (G3) and T1 tumours are further 
treated with bacillus Calmette Guérin (BCG) instillations to delay recurrence and to prevent 
progression. MIBC is treated with cystectomy, radiation or chemotherapy to reduce the 
disease-specific mortality.  
In principle, the major risks for patients with NMIBC after initial treatment include tumor 
recurrence, progression to a higher grade or stage, and for MIBC death due to metastatic 
disease. Conventional clinical and pathologic parameters are widely in use to grade and 
stage tumors in order to predict clinical outcome of BC. For NMIBC, risk scores for 
recurrence and progression have been developed by Sylvester [20] and these have been 
taken up in the EAU (European Association of Urology) guidelines [21]. However, these risk 
scores were based on a cohort of patient from the nineteen eighties, a time when TUR was 
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not followed by an initial installation of a chemotherapeutic drug such as mitomycin C and 
when treatment of patients with high risk NMIBC with BCG was not carried out yet. In 
addition, especially grading has been shown to be rather subjective with considerable 
interobserver variation [22]. Molecular markers such as the specific point mutations in the 
FGFR3 gene that occur in over 75% of stage Ta tumours have been associated with a 
relatively benign disease course [7]. Moreover, reproducibility of the FGFR3 mutation assay 
was shown to be 100%.  Besides the FGFR3 mutations other molecular markers with similar 
performance are necessary to better predict disease course in NMI as well as in MIBC.  
Cystoscopy is the gold standard for surveillance of patients with a previous bladder 
tumour, however, it is an invasive and uncomfortable procedure [23, 24]. Moreover, even 
with cystoscopy, there is 20 to 30% chance to miss a tumour [25, 26]. Due to the high 
recurrence rate, depending on the risk group of the patient, NMIBC patients are monitored 
by cystoscopy every 3-12 months after TUR. This sums to an average of about 20 
cystoscopies per patient in the first decade, thus making BC one of the most expensive 
cancers to treat [27]. Cytological examination of voided urine can identify tumour cells 
with a high sensitivity if a high-grade tumour is present [28]. However, for low stage and 
grade tumours the sensitivity is low. The FGFR3 mutations test is an excellent diagnostic 
test for recurrent cancer in patients presenting with NMIBC if their primary tumour harbors 
a mutation. Evidently, other tests are required for those patients with FGFR3 wild-type 
tumours. 
In the past decade several studies addressed DNA methylation patterns in BC using 
genome-wide studies or studies genes that were shown to be methylated in other 
tumours in order to understand BC pathogensis and to develop biomarkers for the above 
mentioned problems. The aim of the present review is to summarize the literature from 
2001 to April 2012 on DNA methylation based biomarkers for the diagnosis, surveillance, 
prognosis and response to BCG treatment of BC comprehensively.  
 
Evidence acquisition 
The purpose of this review is to summarize the DNA methylation based biomarkers studied 
so far in BC. A PubMed search was performed using MESH terms (Urinary Bladder 
Neoplasms and DNA Methylation) and general search terms (DNA methylation and 
Bladder cancer) until April 2012. This yielded a total of 259 articles. We excluded reviews, 
non-English articles, and studies where these terms were mentioned but not studied, 
reducing the selection to 86 articles.  
 
Evidence synthesis 
DNA methylation studies in BC 
In the past decade several studies were published on DNA methylation based biomarkers 
in BC.  From 2001 to 2008, most studies focused on the genes commonly methylated in 
other cancers. These studies are summarized in the first part of Table 1. Besides the 
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methylation frequency in tumour and normal DNA, Table 1 also indicates if a marker was 
significantly correlated with stage, grade, and occurrence of recurrence, progression or 
survival. From 2009 to 2012 several genome-wide studies (GWS) were performed using 
different approaches.  Below we discuss those studies that identified markers based on a 
genome-wide discovery phase. In the last part of this section we address studies dealing 
with methylation in relation to age and carcinogenic exposure. All studies are taken up in 
Table 1 in a chronological order. 
The first GWS by Nishiyama 2009 [29] used a Bacterial Artificial Chromosome (BAC) array 
based methylated CpG island amplification (BAMCA) to map methylation patterns in 18 
normal urothelia, 17 non-cancerous urothelia from BC patients and 40 BCs. Increased 
methylation levels were reported in these categories of samples, respectively. In addition, 
several of the BAC clones were reported to methylated in BC and few specific for 
predicting recurrence but none of these were validated independently. As there was no 
information of the genes involved, this study was not taken up in Table 1. Wolff 2010 [30] 
used the Illumina GoldenGate methylation assay comprising of 1370 CpG sites selected for 
their frequent methylation in different cancers and studied methylation patterns in 49 
NMIBC, 38 MIBC with matched normal-appearing urothelium, and urothelium from 12 age-
matched BC-free patients. Distinct patterns of hypomethylation in non-invasive tumours 
and widespread hypermethylation in invasive tumours was reported. Methylation of IPF1, 
GALR1, TAL1, PENK and TJP2 was shown to be significantly higher in MIBC, which was 
confirmed by validation using pyrosequencing on independent set of tumours. 
Methylation of ZO2, MYOD and CDH13 were shown to be higher in tumour associated 
normal urothelium but was significantly increased in the corresponding tumour. The 
authors concluded that this indicated the presence of an epigenetic field defect, i.e. 
methylation was already present in normal looking cells before onset of tumorigenesis. 
Chung 2011 [31] used Methylated CpG Island Amplification and Microarray (MCAM) and 
pyrosequencing on 85 primary NMI bladder tumours and 26 MI cystectomy specimens to 
report a panel of 10 genes highly methylated in BC with methylation frequency ranging 
from 62 to 92%. Augustin 2011 [32] studied methylation patterns in different cancer types 
including 44 BC and 8 normal urothelial samples using the same Illumina GoldenGate 
methylation assay as Wolff. The main outcome of the study was the finding of DNA 
methylation fingerprints which are able to identify the origin of cancers of unknown 
primary origin (CUPs).  We were not able to deduce whether the same genes were 
identified by both Wolff and Augustin. Reinert 2011 [33] used the Illumina Infinium 27K 
microarray to map the methylation patterns in 56 bladder tumours and 14 normal 
urothelial samples followed by validation in 63 samples using methylation specific high 
resolution melting (MS-HRM) and bisulfite sequencing. POU4F2 and HOXA9 were reported 
to have the highest frequency of methylation (92%) in BC tissues, while normal urothelium 
was unmethylated. Kandimalla 2012 [34] performed a GWS using the Agilent 244K 
microarray on 44 fresh-frozen BC and subsequently validated the findings using a custom 
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Illumina GoldenGate methylation assay in 77 BC tissues. This resulted in the identification 
of 96 highly methylated CpG islands with a highest methylation frequency of 94% for the 
MEIS1 gene. This study also indicated that, NMIBC FGFR3 wild type tumours were more 
methylated than the FGFR3 mutant tumours.  Vallot [35]  and Costa [36]  took a different 
approach and reported genes methylated and reactivated in bladder cancer cell lines 
using epigenetic reactivating drugs. Vallot 2011 [35] reported that multiple chromosomal 
regions are epigenetically silenced in BC, defined as multiple regional epigenetic silencing 
(MRES) phenotype. However, this was not due to DNA methylation, instead it was because 
of histone methylation and hypoacetylation.  Costa 2010 [36]  reported a panel of three 
genes GDF15, TMEFF2 and VIM studied in 50 BC and 20 normal urothelial samples using 
methylation specific PCR (MSP) and showed a methylation frequency of 100% in tumour 
DNA, while no methylation was observed in normal urothelial tissue. Lin-Hui 2010 [37]  
studied methylation of e-cadherin (CDH1), p16, p14 and RASSF1A in 50 BC tissues and 
associated normal urothelium. In general methylation was observed in both tissue types 
but increased from normal urothelium to BC significantly. p14 hypermethylation was 
found to be associated with shorter recurrence-free survival (p=0.019). Serizawa 2011 [38]  
were the first to combine mutation analysis with methylation. They studied mutation of six 
genes (FGFR3, PIK3CA, TP53, HRAS, NRAS and KRAS) together with promoter methylation of 
11 genes in 101 BC tumours and corresponding urines and 33 controls. Combining FGFR3 
mutations with methylation status of 3 markers (APC, RASSF1A and SFRP2) resulted in 
methylation frequency of 90% and 93% in two independent tumour sets with no 
methylation in normal tissue. 
DNA methylation is associated with age and carcinogenic exposure. Marsit 2006 [39]  
studied methylation of p16, RASSF1A and PRSS3 in a large set of 351 BC and found that 
methylation of p16 and methylation of RASSF1A and PRSS3 were significantly associated 
with smoking and arsenic exposure respectively. Owen 2010 [40]  studied methylation of 8 
tumour suppressor genes (TSG) in younger patients. The methylation index (MI) of these 
TSG increased from younger age group patients to older (MI-37.5 in age group <20, MI-
62.5 in age group 20-45). Sobti 2010 [41]  and Wolff 2008 [42]  showed that methylation 
of DAPK and RUNX3 was significantly associated with age and smoking.  
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Prediction of disease course using DNA methylation 
MIBC and patients who progress to MIBC have a poor survival in spite of radical cystectomy 
and therefore markers predicting progression in this group of patients are urgently 
needed. Progression to MI disease in pTa tumours is much lower than for T1 tumours. 
Several studies have reported genes methylated in BC with a potential of predicting 
progression. Below, we discuss these studies, the details are included in Table 1 in 
chronological order. 
Maruyama 2001 [46] were the first to report methylation based prognostic markers in BC. 
They studied methylation of 10 tumour suppressor genes in BC using MSP in 98 BC 
patients comprising of 15 stage 0, 6 with stage I, 8 with stage II, 18 with stage III, 16 with 
stage IV and 35 cases of unknown stage with a maximum follow-up time of 120 months. 
Methylation of CDH1 or FHIT was shown to be associated significantly with poor survival 
(p=0.003 and 0.04 respectively). CDH1 methylation was shown to be an independent 
predictor of survival in a multivariate analysis (p=0.02). Satyanarayana 2004 [52] showed 
that methylation of the LAMC2 gene studied in 91 BC using MSP was significantly 
associated with survival (p=0.002). These samples comprised MI and NMI tumours, but the 
exact stage information of the 91 tumours was not mentioned. Catto 2005 [53] studied 
methylation of 11 CpG islands using MSP in 116 bladder and 164 upper urinary tract 
tumours with a median follow-up time of 56 months. Methylation was found in 86% of all 
tumours, was noticeably more profound in upper tract tumours than in BC and was 
generally associated with advanced grade, stage, progression and mortality. Methylation 
of RASSF1A, DAPK and MINT31 was associated with tumour progression (p=0.008, 0.014 
and 0.008 respectively). Furthermore RASSF1A and MINT31 methylation were shown to be 
associated with mortality (p=0.018 and 0.007). Multivariate analysis showed that in 
addition to tumour stage (p=0.002) and grade (p=0.025), methylation of RASSF1A 
(p=0.028) and DAPK (p=0.039) were associated with tumour progression. Marsit 2005 [56] 
studied the methylation of WNT antagonist SFRP genes using MSP in 355 BC with a median 
follow-up of 60 months. Overall patient survival was shown to be significantly poorer with 
any SFRP gene methylation (p=0.0003). With a proportional hazard modeling, patients with 
methylation of any SFRP gene revealed a significantly poorer overall survival (p=0.02), 
when controlled for TP53 staining and other survival associated factors. Kim 2005 [55] 
showed methylation of RUNX3 studied in 124 BC using MSP to be associated with tumour 
recurrence (p=0.02) and progression (p=0.01) in NMIBC. Freidrich 2005 [54] studied 
methylation of 20 cancer related genes in 105 BC using methyl light. KM analysis revealed 
that methylation of TIMP3 was significantly associated with recurrence free survival 
(p=0.036). Contrary, patients in which TIMP3 was methylated had a better disease free 
survival than patients without (p<0.05). Yates 2007 [64] performed q-MSP at 17 gene 
promoters suspected to be associated with tumour progression in 96 malignant and 30 
normal urothelial samples. KM analysis revealed 5 loci (RASSF1A, E-Cadherin, TNFSR25, 
EDNRB and APC) to be associated with progression to more advanced stage (p<0.05). 
Multivariate analysis revealed that the overall degree of methylation was more 
DNA methylation based biomarkers in bladder cancer 
39 
 
significantly associated with subsequent progression and death (p=0.002) than tumour 
stage (p=0.008). Moreover likelihood and timing of tumour progression was identified with 
a sensitivity of 97% and specificity of 75% using a predictive model. Aleman 2008 [65] 
described the methylation of SOX9 gene in 101 BC using MSP and showed that it is 
significantly associated with shorter overall survival (p=0.025). Hoque 2006 [86] studied 
methylation of TIMP3 in 175 BC urines (12 months follow up information was available for 
85 urines) using MSP. Univariate analysis showed risk of death was significantly higher in 
patients with high TIMP3 methylation (p=0.01). Multivariate analysis revealed that TIMP3 
methylation was an independent prognostic factor for bladder cancer survival with stage 
and metastasis (p=0.001 and 0.02 respectively). Multivariate Cox regression models 
revealed that RUNX3 methylation status was a strong predictor of tumour progression and 
cancer specific survival. Cebrian 2008 [71] studied methylation of the Myopodin gene in 
466 BC using MSP and showed that its methylation was significantly associated with 
tumour stage, grade, progression and survival (p<0.05). Aleman 2008 [66] studied PMF1 
methylation in 507 BC using MSP and found it was significantly associated with increasing 
stage (p=0.025), Immunohistochemical analyses revealed that PMF1 methylation was 
associated with cytoplasmic PMF1 expression loss (p=0.032) and PMF1 protein expression 
patterns were significantly associated with stage (p=0.001), grade (p=0.001), and poor 
overall survival using univariate and multivariate (p=0.001 and 0.011) analyses. In a large 
series of BC, Marsit 2010 [75] showed that methylation of HOXB2 was associated with 
muscle invasive BC. Alvarez 2010 [77] studied Myopodin methylation in 170 T1G3 BC 
using MSP. Univariate and multivariate analysis revealed that Myopodin methylation was 
associated with an increased recurrence rate (p=0.004), progression (p= 0.002) and shorter 
disease specific overall survival (p =0.020). Myopodin methylation was also shown to be 
associated with BCG response. In a GWS performed by by Reinert 2011 [33] it was found 
that methylation of the TBX4 gene was associated with progression in NMIBC (p<0.04). Yan 
2012 [85] studied methylation of RUNX3 in 186 BC using MSP and showed its significant 
association with progression in univariate and multivariate analysis (p=0.016 and 0.043 
respectively). GWS by Kandimalla  2012 [34] showed that methylation of TBX2, TBX3, 
GATA2 and ZIC4 genes in a test and a validation set  of pTa tumours (n=65) was associated 
with progression (each p<0.003). Multivariate analysis indicated that methylation of TBX3 
and GATA2 are independent predictors of progression when compared to 
clinicopathological variables (p = 0.04 and 0.03, respectively). The predictive accuracy 
improved by 23% by adding methylation of these genes to the European Organization for 
Research and Treatment of Cancer risk scores. Kim Sang 2012 [84] showed that among 
patients with recurrent NMIBC (n=111), RASSF1A methylation was associated with shorter 
time to progression by KM analysis (p=0.004) and identified methylation of this gene as an 
independent predictor of cancer progression by multivariate Cox regression analysis 
(p=0.014). Agundez 2011 [87] studied the methylation status of 25 tumour suppressor 
genes for predicting Bacillus Calmette-Guerin (BCG) response in 91 patients with T1G3 
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high risk BC using MS-MLPA. The genes most frequently methylated in these tumours were 
STK11 (95%), MSH6 (81%), BRCA1 (73%), PAX5A (68%), MGMT (67%), CDH13 (63%), and IGSF4 
(62%). In a multivariate analysis the combination of MSH6 and THBS1 predicted 
progression most significantly (p=0.004). PAX6 and GATA5 predicted recurrence and 
disease specific survival respectively (p=0.025 and 0.037 respectively). Recently Alvarez 
2012 [88] reported methylation PMF1 gene predicting BCG response by studying 108 T1G3 
bladder tumours.  
 
Urine methylation markers for the diagnosis of BC 
Urine methylation markers are promising tools for the surveillance of NMIBC patients to 
spot potential recurrences, and this can reduce the burden of invasive cystoscopy. In the 
past decade several studies described urine methylation markers. However, in all studies, 
except those by Zuiverloon and Kandimalla (see below), markers were tested on urine 
samples that were obtained from patients with both primary and recurrent tumours. As 
primary tumours are often larger and of higher stage and grade, the sensitivity of the 
markers is not realistic for the purpose of surveillance [89]. The markers are discussed 
below and detailed information can be found in Table 2 again in chronological order.  
For the analysis of gene methylation in voided urine different techniques have been used 
like methylation specific PCR (MSP), quantitative methylation specific PCR (Q MSP), 
methylation specific multiplex ligation probe amplification (MS-MLPA), methylation 
specific high resolution melting (MS-HRM) and bisulfite specific single nucleotide primer 
extension (BS-SNaPshot). Using MSP the following studies have determined the sensitivity 
and specificity of markers in urine DNA. Yu 2007 [90] studied methylation of 11 genes in 
urines from 99 patients with a primary and 33 with a recurrent tumour along with 23 
normal urines and reported 92% sensitivity and 87% specificity. Renard 2010 [78] 
identified and validated methylation of TWIST and NID2 in 157 patient urines from primary 
tumours and 339 normal controls with a sensitivity of 84% and specificity of 96%. This was 
higher than the sensitivity of cytology, which was 48%. Dulaimi 2004 [51] studied 
methylation of APC, RASSF1A and p14 in 45 patient urines and 21 normal urines revealing a 
combined sensitivity of 87% and specificity of 100%. Eissa 2012 [91] combined 
methylation of RARB2 with hyaluronidase levels and cytology in 100 patient urines and 111 
control urines, which resulted in a sensitivity of 95% and a specificity of 82%. Yang-Xing 
2012 [92] studied methylation of 5 genes VAX1, KCNV1, TAL1, PPOX1 and CFTR in 212 urines 
comprising of 157 primary and 55 recurrence associated and 190 normal urines to report a 
sensitivity of 89 and specificity of 88%. Q-MSP was used in the following studies. Hoque 
2006 [86] studied methylation of four genes in 175 patient urines comprising of 128 
primary, 29 recurrent and 18 unknown along with 94 control urines to report a sensitivity 
of 69 and a specificity of 100%. Roupret 2008 [93] combined methylation with 
microsatellite analysis on 40 primary tumour urines and reported a sensitivity of 86 and 
specificity of 84%. Costa 2010 [36]  studied methylation of three genes GDF15, TMEFF2 and 
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VIM in 51 patient and 20 control urines to report a sensitivity of 94 and a specificity of 
100%. Serizawa 2011 [38] combined methylation of three genes with FGFR3 mutations in 
101 primary tumour urines and 30 normal urines and reported a sensitivity of 62 and a 
specificity of 100%. Chung 2011 [31] studied methylation of a four gene panel in 128 
patient urines comprising of 88 primary and 40 recurrent along with 110 control urines and 
reported a sensitivity of 81 and a specificity of 97%. Vinci 2011 [82] studied methylation of 
a three gene panel in 108 patient and 105 control urines and reported a sensitivity of 79 
and a specificity of 90%. Reinert 2011 [33] used MS-HRM to study methylation of a four 
gene panel in 115 patient and 59 control urines and reported a sensitivity of 84 and a 
specificity of 96%.  
There are only two studies so far; where solely recurrence associated urines were used to 
investigate the sensitivity of methylation markers. Zuiverloon 2012 [94] used MS-MLPA to 
study methylation of APC, TERT and EDNRB for the detection of recurrent BC in a test (68 
positive and 91 negative urines) and validation set (49 positive and 60 negative urines). 
Sensitivities of 63, 72% were reported for the test and validation set with a specificity of 58 
and 55% respectively. Kandimalla 2012 used a BS-SNaPshot assay to study methylation of 
the OTX1, OSR1 and ONECUT2 for the detection of recurrent bladder tumours in a test and 
validation set consisting of 198 recurrence associated urines and 70 control urines 
together. Combination of methylation assay with the FGFR3 mutation assay resulted in a 
sensitivity of 68%, 79% at a specificity of 90% for the detection of recurrent BC in the test 
and validation set respectively.  
Out of the few serum based methylation markers, Ellinger 2008 [95] studied methylation 
of APC and GSTP1 in 45 normal and 45 patient serum DNA using MSP and reported a 
sensitivity of 80 and specificity of 93%. Valenzuela 2002 [96] studied methylation of p16 in 
86 BC patients and 49 normal serum DNA using MSP, which resulted in a sensitivity of 23% 
and a specificity of 95%.  
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Conclusions 
DNA methylation is a common feature of BC and plays an important role in bladder 
carcinogenesis as well as in disease progression. Wolff [30] and Reinert [102] have shown 
that normal urothelium next to the tumour is methylated, and defined this as an 
epigenetic field defect. This suggests that methylation precedes tumorigenesis. This could 
have implications for urine testing as methylation will persist in the normal urothelium 
after the resection of the tumour. However, this will depend on the extent of epigenetic 
field defect and on the analytical sensitivity of the urine assay. From the studies by Wolff 
and Kandimalla [103] it appeared  that a high proportion of genes that are de novo 
methylated in BC are repressed by PcG complexes in embryonic stem cells. These 
complexes attract DNMTs and aberrant DNA methylation in some cells early in 
development may be the outcome [104]. This again implies that methylation could be an 
early event in tumorigenesis as was first proposed by Feinberg [105]. Serizawa and 
Kandimalla [38, 103] identified that DNA methylation is more profound in NMI FGFR3 wild 
type BC compared to the NMI FGFR3 mutant BC indicating a CpG island methylator 
phenotype (CIMP). Wolff et al also showed that MIBC and NMIBC have different 
methylation patterns. Together these studies show that like the genetic alterations, 
epigenetic alterations also differ between subgroups of BC. Vallot [35] identified that 
multiple chromosomal regions are epigenetically silenced in BC, defined as multiple 
regional epigenetic silencing (MRES) phenotype. However, this was not due to DNA 
methylation, but because of histone methylation and hypoacetylation.   
Urine methylation markers are important for the surveillance of BC to spot potential 
recurrences, which can ultimately decrease the burden of invasive cystoscopy. In most 
studies, however, the sensitivity of the urine markers was assessed on a convenience set of 
urines that comprises urines from primary and recurrent tumours and urines from patients 
with high stage and grade tumours. Before these markers can be used for surveillance, 
they first need to be validated on a representative cohort of patients. So far only two 
studies identified recurrence specific urine methylation markers [94] [103]. The 3-plex 
methylation assay in the study by Kandimalla [103] in combination with the FGFR3 
mutation assay achieved a sensititvity of 79% for recurrent tumour detection. The 
sensitivity of this assay combination is similar to the sensitivity of the current gold standard 
white light cystoscopy with sensitivity in the range of 68 to 83% when compared to the 
more sensitive blue light cystoscopy [106, 107]. Given the comparable sensitivities of urine 
testing and cystoscopy, patients under surveillance for recurrent BC in the 
low/intermediate risk groups could benefit from urine testing followed by cystoscopy only 
when the urine test is positive. This should be validated further in a prospective manner.  
Prediction of progression for patients with NMIBC has been a major clinical challenge. 
Currently prediction of progression in NMIBC is based on the progression scores 
developed by Sylvester [20], that have been taken up in the EAU guidelines. These risk 
scores were based on a cohort of patient from the nineteen eighties, a time when TUR was 
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not followed by an initial installation of a chemotherapeutic drug such as mitomycin C and 
when treatment of patients with high risk NMIBC with BCG was not carried out yet. In 
addition, especially grading has been shown to be rather subjective with considerable 
interobserver variation [22]. Several of methylation markers have been associated with 
disease course in multiple studies. RASSF1A was shown to be associated with progression 
in NMIBC by three dierent studies [53, 64, 108]. CDH1 (e-cadherin), TIMP3, Myopodin and 
RUNX3 were also shown to predict progression in NMIBC in two dierent studies [46, 55, 
64, 71, 77, 85, 86].  All these studies used a mixture of pTa and pT1 tumours except two 
[77][102]. Alvarez [77] who showed that methylation of the Myopodin gene promoter was 
able to predict progression in pT1 tumours. The same group had earlier demonstrated that 
Myopodin was also signicantly associated with progression in a mixture of pTa and pT1 
tumours [71]. Kandimalla [103] identied and validated a set of four genes TBX2, TBX3, 
GATA2 and ZIC4 predicting progression in pTa tumours exclusively and these markers 
improved the accuracy of the EAU scores. Taking survival as endpoint, dierent studies 
have shown that methylation of CDH1, FHIT, LAMC2, RASSF1A, TIMP3, SFRP1, SOX9, PMF1, 
RUNX3 and Myopodin was associated with poor survival in MIBC [46, 52, 54-56, 65, 66, 71, 
77].  
Intravesical bacillus Calmette-Guerin (BCG) immunotherapy is a successful therapy for 
patients with high grade NMI tumours [109]. A signicant portion of these patients fail to 
respond to BCG therapy and their tumours not only persist or recur, but they may become 
invasive or metastatic [110]. To predicted BCG response in T1G3 bladder tumours, 
methylation of a set of tumour suppressor genes and methylation of PMF1 were identied 
and validated [87, 88]. 
To conclude, several very promising biomarkers based on DNA methylation have been 
identied for diagnosis, prediction of progression and survival and for therapy response. 
Several of these markers were validated in retrospective studies. To bring these promising 
markers to the clinic, it is necessary to perform large prospective multicenter validation 
studies.  It is recommended that future studies should adhere to STARD [111] and REMARK 
[112] guidelines when reporting diagnostic and prognostic markers as this was not the 
case with many studies presented in this review. 
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Abstract  
Background 
DNA methylation markers could serve as useful biomarkers, both as markers for 
progression and for urine-based diagnostic assays. 
 
Objective 
To identify bladder cancer specific methylated DNA sequences for predicting pTa specific 
progression and detecting bladder cancer in voided urine.  
 
Design, setting and participants 
Genome-wide methylation analysis was performed on 44 bladder tumors using Agilent 
244k human CpG island microarrays. Validation was done using a custom Illumina 384-plex 
assay in a retrospective group of 77 independent tumors. Markers for progression were 
identified in pTa (n=24) tumors and validated retrospectively in an independent series of 
41 pTa tumors by the SNaPshot method. 
 
Measurements 
The percentage methylation in tumor and urine samples was used to identify markers for 
detection and related to the endpoint progression to muscle-invasive disease with Kaplan-
Meier models and multivariate analysis. 
 
Results and limitations 
In the validation set, methylation of the TBX2, TBX3, GATA2 and ZIC4 genes was associated 
with progression to muscle-invasive disease in pTa tumors (p=0.003). Methylation of TBX2 
alone showed a sensitivity of 100%, a specificity of 80%, PPV of 78% and NPV of 100% with 
an AUC of 0.96 (p<0.0001) for predicting progression. Multivariate analysis showed that 
methylation of TBX3 and GATA2 are independent predictors of progression when 
compared to clinicopathological variables (p=0.04 and 0.03 respectively). The predictive 
accuracy improved by 23% by adding methylation of TBX2, TBX3 and GATA2 to the EORTC 
risk scores. We further identified and validated 110 CpG islands that are differentially 
methylated between tumor cells and control urine. The limitation of this study is the small 
number of patients analyzed for testing and validating the prognostic markers.  
 
Conclusions 
We have identified 4 methylation markers that predict progression in pTa tumors thereby 
allowing stratification of patients for personalized follow-up. In addition, we identified CGIs 
that will enable detection of bladder tumors in voided urine.  
 
Key words 
Bladder cancer, DNA methylation, Biomarkers, Epigenetics, Progression, Prognostic 
markers  
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Introduction 
Urinary bladder cancer is the fifth most common cancer in the western world [1]. Bladder 
tumors present either as non-muscle (stages pTa, pT1 and CIS) or as muscle-invasive 
carcinomas (stage >pT1), and are associated with different genetic changes. Somatic 
mutations in the FGFR3 gene accompanied with losses of chromosome 9 are more 
frequent in NMIBC (Non-muscle invasive bladder cancer), while TP53 mutations are 
associated with MIBC (Muscle-invasive bladder cancer) [2-4]. Patients diagnosed with MIBC 
and those who progress to MIBC have an unfavourable prognosis, despite radical 
cystectomy and chemotherapy.  
pTa tumors represent about 60% of all bladder tumors upon presentation. Progression to 
MI disease in pTa tumors is much lower than for T1 tumors, however, the risk is still 10% 
and up to 60% of patients will have on average 3 recurrences, warranting long-term 
surveillance [5-7]. Until now, no good biomarkers are available that predict progression in 
this large subgroup of BC. The long survival of NMIBC patients and the need to monitor 
them makes BC the most costly cancer when calculated per patient. In recent years, it 
became clear that recurrent BC can be detected using urine-based assays [8]. In this 
context, we have previously shown that loss-of-heterozygosity (LOH) by microsatellite 
analysis or detection of FGFR3 mutations in DNA isolated from urine is able to predict the 
presence of recurrent bladder tumors [9, 10]. As these assays do not cover all bladder 
tumors, additional biomarkers are required.   
Epigenetic modifications, such as DNA methylation, contribute to the pathogenesis of 
various cancers, including BC. Cancer-associated hypermethylation of CGIs may serve as a 
useful biomarkers for diagnostic, prognostic and predictive purposes. For instance, 
methylation of the MGMT gene is associated with sensitivity of patients with glioblastoma 
for temozolomide therapy [11]. To identify the best bladder-specific epigenetic 
biomarkers, we performed a genome-wide screen for DNA methylation in BC.  
 
Materials and methods 
Patient samples, ethics statement 
For the genome-wide study using Agilent arrays, we collected 44 freshly frozen bladder 
cancer (BCa) tissues, representing 29 non-muscle invasive (NMI) tumours (19 with FGFR3 
mutation (NMI-MT) and 10 without (NMI-WT)), and 15 muscle-invasive (MI) tumours via the 
department of Urology at Erasmus MC, Rotterdam. For the Golden Gate Methylation  
(GGMA) validation assay, we used a retrospective group of 77 formalin-fixed, paraffin-
embedded (FFPE) BCa samples (23 Ta NMI-MT, 10 Ta NMI-WT, 7 T1-MT, 13 T1-WT, 24 MI) 
collected from the department of Pathology at our institute. This set of tumours consist of 
5 Ta progressors and 19 Ta non-progressors from individual patients with a median follow 
up time of 60 mo, which we considered as a test set to find prognostic markers. For the 
validation of progression markers in an independent set of tumours, we used DNA from a 
retrospective group of fresh frozen tissue of 22 non-progressors and 19 progressors with a 
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median follow up time of 88 mo collected via the department of Urology at Erasmus MC. 
The median age of these patients was 68 yr. Ten patients were female. Generally, all 
patients were followed and treated according to the guidelines of the European 
Association of Urology [12]. Progression in both groups was defined as progression from 
Ta NMI-BCa (NMI-BC) to MI-BCa (MI-BC) as determined by pathology. We have used the 
REMARK criteria to address the prognostic markers [13]. The medical-ethical committee at 
Erasmus MC approved the project. All patients have given written informed consent. 
Patient data for the tumours included can be found in Supplementary Table S1-3 
(http://www.europeanurology.com/article-asset/S0302-2838(12)00013-9/mmc1/pdf/). 
FFPE samples were used according to the standards presented in “The Code for Proper 
Secondary Use of Human Tissues in the Netherlands” (http://www.federa.org/). Tumour 
samples were included only if at least 80% of the sample consisted of cancer cells, as 
verified by H&E staining. Tumour samples were extracted from FFPE tumor tissue by de-
waxing with xylene and ethanol. Tumour DNA from FFPE and fresh frozen tissue was 
isolated using the DNeasy Tissue kit (Qiagen, Hilden, Germany), according to the protocol. 
Commercially available normal human genomic blood DNA (Promega, Madison, WI, USA) 
was used as a reference in the genome-wide study. As reference DNA in the GGMA 
validation assay we used DNA isolated from cells present in the normal urine of four 
healthy men aged >50 yr. Urine was collected and assessed for leukocytes, erythrocytes 
and nitrite using Multistix® 8 SG. Each sample was centrifuged for 10 minutes at 3,000 rpm. 
Cell pellets were washed once with 10 ml phosphate buffered saline, resuspended in 1 ml 
phosphate buffered saline, transferred to an Eppendorf vial and centrifuged for 5 minutes 
at 6,000 rpm. Supernatant was discarded and each cell pellet was stored at −20°C until 
DNA isolation. DNA was extracted from the cell pellet using the QIAamp DNA mini-kit 
according to the manufacturer protocol. All analyses were done with blinded sample 
information. 
 
Differential Methylation Hybridization (DMH) and Data Analysis 
DNA amplicons were prepared for hybridization according to the differential methylation 
hybridization (DMH) protocol, originally described by Yan et al [14] and modified according 
to Stumpel et al [15]. Briefly, 0.5 µg of genomic DNA was digested with the four base 
(T^TAA) restriction enzyme MseI, which restricted genomic DNA into fragments <250 bp in 
length, while leaving the GC-rich CpG islands (CGIs) relatively intact. Subsequently, the 
sticky ends of the fragments were ligated to linkers. The samples were then digested with 
the methylation-sensitive restriction enzymes HpaII and BstUI. Reference samples were 
treated in the same way to generate amplicons. Polymerase chain reaction (PCR; 20 cycles) 
was performed using the purified, digested, linker-ligated DNA as template to generate 
final target amplicons, followed by coupling to fluorescent dyes (Cy3 in the case of human 
genomic reference DNA and Cy5 in the case of tumor samples) before hybridizing to the 
Agilent 244K CpG island microarray. The pooled amplicons were co-hybridized on the 
array. Using this approach, genomic DNA fragments containing unmethylated CpG sites in 
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one sample (e.g. the human genomic reference DNA) were degraded by restriction 
digestion, and not amplified. However, corresponding DNA fragments in the other sample 
(the bladder tumor) that contain methylated restriction sites were protected from 
digestion and subsequently amplified by PCR. Differentially methylated sequences were 
identified by comparing hybridization signals between fluorescently labeled tumor (Cy5) 
and reference (Cy3) amplicons. Labeling and hybridization of the arrays were performed at 
Service XS (Leiden, the Netherlands), which also provided the quality control reports about 
the hybridization and performance of the arrays according to the manufacturers 
recommendation. All the arrays passed the quality parameters described by the Agilent 
technologies (Agilent feature extraction software (v9.5) reference guide). 
All microarray data generated is compliant with current Minimum Information About a 
Microarray Experiment (MIAME) standards according to Brazma et al [16, 17]. 
Normalization, preprocessing of raw data and statistical analysis were done using 
Bioconductor packages in an R programming environment (http://www.r-project.org/). 
Raw hybridization signals were normalized by applying the within-array global “lowess” 
normalization method [18], which assumes that the bulk of the probes on the array are not 
differentially expressed. Because the normalization also includes a pre-processing step, the 
normalized intensities were log2-transformed. The log2-transformed intensities were then 
subjected to further statistical testing to determine which loci were differentially 
methylated. For this, we applied the linear model “limma” [19], to fine differentially 
methylated genes in bladder tumours vs normal and between all different subgroups. 
These comparisons are analogous to a classical two-sample t-test analysis.  
The p-value threshold was calculated using the Benjamini and Hochberg method [20]. Loci 
corresponding to a p-value of <0.05 and a log fold change of either greater than 0.5 or less 
than -0.5 and with more than 2 probes from the same CGI were classified as differentially 
methylated. We choose to use Log fold change of plus or minus 0.5 as an arbitrary cutoff to 
end up with a reasonable number (not too much or too low) of probes for further 
validation. 
 
Illumina custom Golden Gate Methylation assay and statistical analysis 
We designed GGMA interrogating 384 CpG-containing probes representing 238 CGIs. We 
selected the probes based on the identified differentially methylated loci in the genome-
wide analysis. The methylation assay is an adaptation of the Illumina high-throughput SNP 
genotyping assay described by Fan et al [21]. Briefly, nonmethylated cytosines were 
converted to uracil by treatment with bisulfite. Sodium bisulfite modification of genomic 
DNA was carried out using the EZ DNA Methylation Gold Kit (Zymo Research Corp, Orange, 
CA, USA) according to the manufacturer’s protocol, using 0.8 µg of DNA. The bisulfite 
conversion efficiency was monitored by PCR with BS-specific primers. Arrays were run at 
Service XS according to the manufacturer’s protocol and as described by Bibikova et al 
[22]. Data were analyzed with Illumina’s BeadStudio Methylation module software. All 
array-data points were represented by fluorescent signals from both methylated (M) and 
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unmethylated (U) alleles. The average methylation value β was derived from 
approximately 30 replicate methylation measurements for each locus. The methylation 
level was given by β = (max(M, 0))/(|U|+ |M| + 100). The β-value (0 ≤ β ≤ 1) reflects the 
methylation level of each CpG site, where 1 represents fully methylated and 0 represents 
unmethylated. At each locus for each sample, the detection p-value was defined as 1 
minus p-value computed from the background model, characterizing the chance that the 
signal was distinguishable from negative controls. Using this as a metric of quality control 
for sample performance, we dropped 13 FFPE samples from the analysis, because they 
either had very low overall signal intensities or > 25% of loci failed. Differences in 
methylation between loci were considered when the average β-value ratio was larger than 
1.2 and/or the difference between the average β-value (Δβ) was > 0.1. 
 
Validation of prognostic markers and statistical evaluations 
We used the Bisulfite Specific-Snapshot method described by van Oers et al [9] to validate 
our prognostic markers. Leave-one-out crossvalidation (LOOCV) method was used to re-
check the prognostic markers found as significant by student t-test and log-rank test, and 
the best probes were validated in an independent set of tumours by BS-Snapshot (A list of 
primers and probes used is given in Supplementary Table S4). The method involves 
bisulfite conversion of genomic DNA (EZ DNA methylation gold kit, Zymo Research Corp, 
Orange, CA, USA), followed by subsequent amplification of interesting CGIs. The PCR 
products were treated with two units of Exonuclease I (ExoI) and three units of Shrimp 
Alkaline Phosphatase (SAP; USB, Cleveland, Ohio USA). This was followed by a single-
nucleotide probe- extension assay using a SNaPshot Multiplex kit (Applied Biosystems, 
Foster City, CA) and probes designed to anneal to either the forward strand or the reverse 
strand of a PCR product adjacent to the mutation site of interest. These probes were fitted 
with T-tails of different length at their 5’ ends to allow separation of the extension products 
by size [23]. The mutation detection reactions were performed in a total volume of 10 µl 
containing 2 µl SAP/ExoI treated PCR product, 2.5 µl SNaPshot Multiplex Ready Reaction 
mix, 1 x Big Dye sequencing buffer, and 1 µl probe mix. Thermal cycler conditions were: 25 
cycles of 10 seconds at 95˚C, 5 seconds at 50˚C, and 30 seconds at 60˚C. The products were 
treated with 1 unit SAP at 37°C for 60 min, and at 75°C for 15 min, and were analyzed on an 
automatic sequencer (ABI PRISM 3130 XL Genetic Analyzer, Applied Biosystems) with the 
fluorescent label on the incorporated ddNTP indicating the presence or absence of a 
mutation. For analysis of the data, we used GeneMarker Software version 1.7 (SoftGenetics, 
State College, PA, USA). Methylation percentages were calculated by using the formula: 
Height of the C/G-peak / (Height of the C/G-peak + Height of the T/A peak) x 100.   
 
Statistical evaluations 
Statistical analyses were completed using SPSS v. 15.0 (IBM Corp. Arnmonk, NY, USA). 
Differences were considered significant when P-values were below 0.05. Survival curves 
were calculated using the Kaplan-Meier method, with significance evaluated by two-sided 
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log-rank statistics. Progression free survival was measured from the day of surgery until 
progression to MI disease. A multivariate Cox regression model was used to test the 
independent prognostic relevance of clinical/investigational factors and methylation 
markers. Only patients for whom the status of all variables was known were included in the 
proportional hazard models. The clinical variables age at diagnosis, multiplicity, 
histological grade, tumor size, previous recurrence and adjacent CIS were dichotomized 
(<65 vs >65 years, G1-2 vs G3, <3 cm vs >3 cm, yes vs no). [24] 
 
Results 
A genome-wide methylation profile for bladder cancer 
The study design is described in Figure 1. Patient characteristics are given in Table 1. To 
investigate global DNA methylation in BC, we analyzed 44 bladder tumors with 
microarrays containing 244,000 CpGs. We found 731 probes representing 392 unique CpG 
islands to be methylated in BC. We clustered the different bladder tumor subgroups on the 
basis of all probes differentially methylated between the respective subgroups (Figure 2). 
These analyses showed that subgroups can be identified on the basis of their methylation 
patterns. NMI-WT tumors showed a 3.9 to 5.5 times higher number of hypermethylated 
genes than NMI-MT and MI. Polycomb group (PcG) target genes have been shown to be 
particularly prone to DNA methylation in cancer [25, 26]. Notably, we found that 56.5% of 
the hypermethylated genes in BC were PcG target genes (results not shown).  
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Figure 1: Study design CGI= CpG Island; GGMA= Golden Gate Methylation Assay. 
  
Genome-wide analysis of DNA-
methylation using Agilent 244k    
Human CpG island Microarray 
 (n=44 tumors) 
Analysis of 384 probes representing 
238 unique CGI’s with a custom 
Illumina 384-plex GGMA (n=77 tumors) 
Results: Validated 110 CGI’s 
methylated in bladder tumors, but 
not in the normal urines from age 
matched controls 
Results: Discovered 731 significant 
probes representing 392 unique CGI’s 
methylated in all bladder tumors 
Validation 
Discovery 
Analysis of 15 CGIs by log-rank test, leave 
one out cross-validation test resulted in 9 
significant CGIs 
Results: Validated 4 of 6 CGIs in an 
independent series of pTa tumours using 
BS-SnaPshot assay (n=41) 
Discovery 
Results: Discovered 15 CGIs significantly 
associated with progression from pTa to 
muscle invasive tumours (n=24) 
Validation 
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Table 1: Patient characteristics 
Clinical Parameter Discovery set  (Agilent, n=44) 
Prognostic marker test set  
(n=24) 
Prognostic marker validation set 
( n=41) 
Gender    
    Male 38 16 29 
    Female 6 8 12 
    Unknown 0 0 0 
Age    
    <65 15 14 16 
    >65 29 10 25 
    Unknown 0 0 0 
Post operative treatment    
    Yes 15 3 22 
    No 6 8 12 
    Unknown 23 13 7 
Primary/Recurrent    
    Primary 24 11 32 
    Recurrent 19 13 9 
    Unknown 1 0 0 
Previous recurrence    
    Yes 15 6 9 
    No 28 16 32 
    Unknown 1 2 0 
Multiplicity    
    Solitary 23 9 20 
    Multiple 20 12 21 
    Unknown 1 3 0 
Adjacent CIS    
    Yes 4 1 4 
    No 39 20 37 
    Unknown 1 3 0 
Tumor Size    
    <3 cm 17 8 23 
    >3 cm 4 5 13 
Unknown 23 11 5 
T category    
    Ta 26 24 41 
    T1 3 0 0 
    T2 12 0 0 
    T3 3 0 0 
Grade    
    G1 8 6 15 
    G2 23 15 24 
    G3 13 3 2 
Progression    
    Yes 4 5 19 
    No 25 19 22 
    Unknown 0 0 0 
Survival    
    Yes 31 20 17 
    No 13 4 20 
    Unknown 0 0 4 
Cause of Death    
    Malignant disease 5 2 12 
    Other 8 2 4 
    Unknown 0 0 4 
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Figure 2: Comparison of methylation patterns between BC subgroups. (A) Unsupervised principal component 
analysis with all probes present on the 244K Agilent array:  the NMI-WT (Non-muscle invasive FGFR3 wild 
type) bladder tumor group clusters separately from the NMI-MT (Non-muscle invasive FGFR3 mutant) and MI 
tumors (Red: MI, Blue: NMI-MT and Green: NMI-WT), (B) Venn diagram showing the number of genes that are 
hypermethylated in a specic group of bladder tumors, (C) Semi-supervised analyses for bladder tumor 
subgroups by hierarchical clustering of NMI-MT vs NMI-WT tumors, MI vs NMI-WT tumors and NMI-MT vs MI 
tumors, (D) Principal component analyses for bladder tumor subgroups as in (C). 
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Table 2: Hypermethylated genes and CGIs in bladder cancer 
CGI Symbol Fold Change 
 chr2:6652593
 
MEIS1 4.8 
chr15:946887
 
NR2F2 2.9 
chr13:941521
 
SOX21 2.8 
chr13:349505
 
MAB21L1 2.7 
chr2:6313453
 
OTX1 2.7 
chr19:637845
 
MGC2752 2.6 
chr16:528731
 
IRX3 2.6 
chr14:362052
 
PAX9 2.6 
chr6:1549606
 
FOXC1 2.5 
chr7:9648815
 
DLX5 2.5 
chr7:9648990
 
DLX5 2.5 
chr2:1568926
  
NR4A2 2.5 
chr2:1568938
 
NR4A2 2.5 
chr17:380892
 
CNTNAP1 2.4 
chr6:1338049
 
FOXF2 2.4 
chr10:944413
 
HHEX 2.3 
chr1:2072175
 
PRKCZ 2.3 
chr1:2106293
 
PRKCZ 2.3 
chr7:2716470
 
HOXA7 2.3 
chr5:1740912
 
MSX2 2.3 
chr8:1422883
 
SLC45A4 2.2 
chr2:1115916
 
FLJ44006-
 
2.2 
chr19:405992
 
MAP2K2 2.2 
chr7:1552884
 
SHH 2.2 
chr13:496055
 
chr13 2.2 
chr7:2082894
 
MAD1L1 2.2 
chr17:440743
 
hsa-mir-196a-
 
2.2 
chr7:8449658
 
NXPH1 2.2 
chr18:518624
 
chr18 2.1 
chr10:218286
 
C10orf114 2.1 
chr2:4501493
 
SIX3 2.1 
chr2:4501339
 
SIX3 2.1 
chr6:1053030
 
TFAP2A 2.1 
chr6:1049802
 
TFAP2A 2.1 
chr15:744145
 
ISL2 2.1 
chr15:744193
 
ISL2 2.1 
chr2:7098470
 
VAX2 2.0 
chr7:2724531
 
AMZ1 2.0 
chr17:588653
 
CYB561 2.0 
chr2:1767376
 
HOXD3 2.0 
chr6:1010038
 
SIM1 2.0 
chr6:1010024
 
SIM1 2.0 
chr13:105943
 
EFNB2 1.9 
chr2:1713847
 
GAD1 1.9 
chr4:4915358
 
MSX1 1.9 
chr4:4910534
 
MSX1 1.9 
chr14:371371
 
FOXA1 1.9 
chr6:2267756
 
HDGFL1 1.9 
CGI Symbol Fold Change 
 chr13:495959
 
chr13 1.8 
chr16:873724
 
chr16 1.8 
chr7:2725116
 
EVX1 1.8 
chr5:5455481
 
UNG2 (CCNO) 1.8 
chr18:532541
 
ONECUT2 1.8 
chr21:439021
 
HSF2BP 1.8 
chr1:1193506
 
chr1 1.8 
chr1:6355498
 
FOXD3 1.8 
chr20:225148
 
FOXA2 1.8 
chr20:225107
 
FOXA2 1.8 
chr20:225055
 
FOXA2 1.8 
chr6:1019534
 
GRIK2 1.8 
chr2:4524937
 
chr2 1.8 
chr14:601787
 
SIX1 1.8 
chr7:2717044
 
HOXA9 1.8 
chr1:4767171
 
FOXD2 1.7 
chr1:4768230
 
FOXD2 1.7 
chr1:4767224
 
FOXD2 1.7 
chr14:361228
 
NKX2-8 1.7 
chr19:634200
 
ZNF274 1.7 
chr20:600616
 
TAF4 1.7 
chr2:4508528
 
SIX2 1.7 
chr8:1459093
 
chr8 1.7 
chr4:3033030
 
PCDH7 1.7 
chr4:1117744
 
PITX2 1.7 
chr2:8521346
 
TCF7L1 1.7 
chr6:1049295
 
chr6 1.7 
chr8:1062402
 
SOX7 1.7 
chr12:527269
 
HOXC4 1.7 
chr5:1343909
 
PITX1 1.7 
chr5:1407906
 
PCDHGA12 1.6 
chr6:1704228
 
chr6 1.6 
chr19:609070
 
EPN1 1.6 
chr7:9646932
 
DLX6 1.6 
chr2:1767231
 
hsa-mir-10b 1.6 
chr2:1767206
 
hsa-mir-10b 1.6 
chr21:369900
 
SIM2 1.6 
chr12:184400
 
CACNA2D4 1.6 
chr7:2714913
 
HOXA5 1.6 
chr2:1058642
 
NCK2 1.6 
chr2:1942444
 
OSR1 1.6 
chr17:759360
 
C17orf27 
 
1.6 
chr6:1690517
 
chr6 1.6 
chr2:1766523
 
EVX2 1.5 
chr10:768251
 
ZNF503 1.5 
chr5:9293199
 
chr5 1.5 
chr17:764041
 
KIAA1303 1.5 
chr17:763901
 
KIAA1303 1.5 
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Validation of hypermethylated CGIs 
We validated the selected CGIs on a custom 384-plex Illumina platform (GGMA). We 
included CGIs methylated in all bladder tumors (Table 2) and CGIs dierentially methylated 
between bladder tumour subgroups. Hierarchical clustering clearly separated the bladder 
tumors from blood and normal urine (Figure 3A). We found 217 of 384 probes methylated 
in BC. Of these 203 probes (93.5%) from 133 CGIs were also methylated on the Agilent 
array. We also included DNA isolated from urine of healthy individuals on the GGMA array. 
These cells are derived from normal urothelium and serve as a control in the selection of 
cancer-associated methylated CGIs that can be used to detect primary and recurrent 
tumors in urine DNA. In total, we discovered 110 CGIs that are methylated in bladder 
tumors but not in control urine-derived DNA (Figure 3B and Table 3). A urine test based on 
the best performing CGIs is in development and will be the subject of a separate paper. 
  
Figure 3: Identication and validation of probes useful for urine diagnosis (A) Hierarchical clustering of GGMA 
data of all the investigated samples. The BC samples cluster separately from normal blood and urine samples. 
(B) Heat map showing the probes which are methylated in all tumor subgroups vs blood and urine. (C) 
Methylation status of CpGs in the GATA2, TBX2 and TBX3 CGIs as detected with BS-Snapshot. Depending on 
whether the probe used is hybridizing to the sense or the antisense strand, black/blue peaks represent 
methylated CpGs (C or G), red/green peaks represent umethylated CpGs (T or A) after bisulte conversion. P: 
progressor, N: non-progressor. 
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Table 3: Overview of the CGIs differentially methylated between tumor and control urine 
CpG island location  Gene Name 
Average Beta Ratio 
Cancer vs Urine 
Delta beta 
Cancer vs Urine 
chr18:53254153-53259851 ONECUT2 27.2 0.5 
chr7:27170441-27172987 HOXA9 15.9 0.5 
chr21:36990064-36995761 SIM2 13.6 0.6 
chr2:119329502-119332035 EN1 12.8 0.4 
chr4:147778656-147781351 POU4F2 12.2 0.3 
chr1:178464743-178471598 LHX4 12.0 0.3 
chr4:30330303-30333940 PCDH7 11.8 0.6 
chr2:176652334-176656692 EVX2 11.1 0.5 
chr11:115955870-115957122 chr11 10.8 0.2 
chr10:102986025-102986636 LBX1 10.8 0.2 
chr1:219134071-219134808 HLX1 10.7 0.2 
chr7:121727243-121727884 FEZF1 10.5 0.6 
chr1:47682300-47683607 FOXD2 10.2 0.2 
chr8:65662303-65662699 BHLHB5 10.0 0.4 
chr4:134291113-134293078 PCDH10 9.8 0.2 
chr1:163590111-163590435 LMX1A 9.2 0.4 
chr3:148619591-148620015 ZIC1 8.9 0.2 
chr2:19424445-19425131 OSR1 8.8 0.5 
chr3:148591199-148594390 ZIC4 8.6 0.3 
chr18:26875488-26877115 DSC3 8.5 0.1 
chr10:26544390-26547440 GAD2 8.3 0.2 
chr2:156893804-156894601 NR4A2 7.8 0.7 
chr2:66525936-66527140 MEIS1 7.4 0.6 
chr14:37137198-37138958 FOXA1 7.3 0.4 
chr2:63134539-63134851 OTX1 7.2 0.5 
chr10:21828640-21829594 C10orf114 7.2 0.4 
chr2:111591678-111597436 FLJ44006-BCL2L11 7.0 0.4 
chr3:62331811-62332352 FEZF2 6.0 0.1 
chr1:232106922-232108080 SLC35F3 5.7 0.5 
chr10:76825135-76839606 ZNF503 5.5 0.5 
chr10:124891898-124892607 HMX2 5.4 0.5 
chr16:47868915-47869809 CBLN1 4.5 0.4 
chr15:58083428-58085812 FOXB1 4.5 0.2 
chr4:122521018-122521740 GPR103 4.5 0.2 
chr2:85213468-85216104 TCF7L1 4.4 0.6 
chr2:70984709-70985764 VAX2 4.2 0.6 
chr5:92931996-92934631 chr5 4.2 0.4 
chr1:47672249-47672972 FOXD2 4.0 0.3 
chr7:32768010-32768497 chr7 4.0 0.6 
chr18:68359955-68362770 CBLN2 4.0 0.2 
chr1:63554983-63563059 FOXD3 3.9 0.3 
chr19:57648469-57649057 chr19 3.9 0.3 
chr2:115635208-115637235 DPP10 3.9 0.2 
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CpG island location  Gene Name 
Average Beta Ratio 
Cancer vs Urine 
Delta beta 
Cancer vs Urine 
chr5:140790679-140792801 PCDHGA12 3.7 0.4 
chr18:5186244-5187389 chr18 3.7 0.3 
chr3:129688183-129694961 GATA2 3.5 0.4 
chr13:94152191-94153185 SOX21 3.5 0.5 
chr14:36122886-36123441 NKX2 3.4 0.3 
chr7:27164708-27165039 HOXA7 3.4 0.6 
chr5:134390992-134393045 PITX1 3.4 0.4 
chr19:63420090-63420541 ZNF274 3.4 0.4 
chr6:101953488-101953856 GRIK2 3.2 0.3 
chr17:67627870-67631593 SOX9 3.2 0.2 
chr6:101003802-101004342 SIM1 3.2 0.4 
chr5:122461778-122463450 chr5 3.0 0.2 
chr8:57520681-57521969 PENK 3.0 0.5 
chr15:58079172-58079459 FOXB1 2.8 0.1 
chr12:94776152-94776377 SNRPF 2.8 0.4 
chr8:10624024-10624296 SOX7 2.7 0.2 
chr7:8449658-8450236 NXPH1 2.7 0.4 
chr1:119333515-119333719 TBX15 2.7 0.5 
chr2:42182944-42183157 chr2 2.6 0.1 
chr2:45085286-45086054 SIX2 2.5 0.4 
chr20:54012011-54014085 CBLN4 2.5 0.3 
chr10:102497473-102499636 PAX2 2.4 0.2 
chr2:176737660-176738187 HOXD3 2.2 0.4 
chr21:33316999-33322115 OLIG2 2.2 0.1 
chr13:34950554-34951119 MAB21L1 2.2 0.4 
chr4:111774415-111774953 PITX2 2.2 0.4 
chr8:65653638-65653873 BHLHB5 2.1 0.2 
chr20:22505518-22507240 FOXA2 2.1 0.2 
chr12:52726910-52727810 HOXC4 2.1 0.4 
chr2:171384799-171385226 GAD1 2.1 0.4 
chr15:35174679-35174906 MEIS2 2.0 0.4 
chr2:72224630-72228512 CYP26B1 2.0 0.1 
chr7:155288454-155292175 SHH 1.9 0.4 
chr7:96488158-96489487 DLX5 1.9 0.2 
chr6:101002495-101002783 SIM1 1.8 0.4 
chr7:96469320-96469736 DLX6 1.8 0.3 
chr15:94705727-94706054 chr15 1.8 0.4 
chr10:94441310-94441717 HHEX 1.8 0.3 
chr12:113589232-113589931 TBX3 1.7 0.1 
chr6:1338049-1339169 FOXF2 1.7 0.3 
chr8:72916429-72917309 MSC 1.7 0.3 
chr8:65661156-65661382 BHLHB5 1.7 0.2 
chr1:71284813-71286392 PTGER3 1.7 0.2 
chr7:96489900-96490182 DLX5 1.6 0.3 
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CpG island location  Gene Name 
Average Beta Ratio 
Cancer vs Urine 
Delta beta 
Cancer vs Urine 
chr6:1549606-1560865 FOXC1 1.6 0.1 
chr19:4059920-4060207 MAP2K2 1.6 0.2 
chr5:174091287-174092335 MSX2 1.5 0.3 
chr14:60178708-60179539 SIX1 1.5 0.2 
chr14:98781593-98783184 BCL11B 1.5 0.3 
chr16:52873104-52882105 IRX3 1.5 0.2 
chr13:49595986-49600287 chr13 1.4 0.3 
chr5:54554812-54555385 UNG2 1.4 0.2 
chr15:94688798-94689034 NR2F2 1.4 0.2 
chr14:36205265-36206099 PAX9 1.4 0.3 
chr2:43251545-43251780 chr2 1.4 0.3 
chr7:27219207-27220360 chr7 1.4 0.2 
chr12:113657998-113659205 chr12 1.3 0.2 
chr7:2082894-2083307 MAD1L1 1.3 0.2 
chr10:22804715-22807056 chr10 1.3 0.2 
chr19:63784504-63785085 MGC2752 1.3 0.2 
chr17:75531280-75531511 TBC1D16 1.3 0.2 
chr2:176723195-176723460 hsa-mir-10b 1.3 0.2 
chr7:27100623-27100828 HOXA1 1.3 0.1 
chr2:45249374-45251690 chr2 1.2 0.2 
chr12:1844001-1845219 CACNA2D4 1.2 0.1 
chr5:140724146-140724826 PCDHGA5 1.2 0.1 
chr17:44074360-44075233 hsa-mir-196a-1 1.2 0.1 
 
Identification and validation of CGIs predicting progression 
The GGMA validation assay contained 5 pTa progressors and 19 pTa non-progressors from 
individual patients with a median follow up time of 60 months. This we considered as a 
test set to find prognostic markers. Performing a student t-test identified 15 CGIs (18 
probes) associated with progression to MIBC (Supplementary Table S5). A log-rank test and 
leave-one-out cross-validation test reduced the number to 9 CGIs. We successfully 
designed a bisulfite PCR-SNaPshot assay (Figure 3C) for 6 of these CGIs and tested them in 
an independent validation set of pTa tumors comprising 19 progressors and 22 non-
progressors with a median follow up time of 88 months. This allowed us to confirm that 
methylation of 4 CGIs in the TBX2, TBX3, GATA2 and ZIC4 genes was associated with 
progression. For TBX2, TBX3 and GATA2 any methylation was associated with progression, 
whereas ZIC4 was methylated in most tumors, however, very high methylation (over 45%) 
was associated with progression. Univariate analysis showed that all clinical factors except 
tumor size and adjacent CIS along with TBX2, TBX3, GATA2 and ZIC4 methylation were 
associated with progression. Multivariate analysis showed that TBX3 and GATA2 are 
independent predictors of progression (Table 4). Kaplan-Meier curves for these 4 CGIs for 
both the test set (GGMA) and the validation set are shown in Figure 4A and 4B. Sensitivity, 
specificity, NPV and PPV of the markers are given in Table 5. The EORTC risk scores were 
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significant in predicting progression in univariate analysis, P=0.012, log rank test (Figure 
5A). The predictive accuracy of the EORTC model for progression information was 72.7%. 
The improvement in predictive accuracy by adding methylation percentages (TBX2, TBX3 
and GATA2) was 23.3 %, resulting in a predictive accuracy of 96% for the model with 
methylation markers as determined by AUC (Area under the curve). The major part of this 
effect was caused by the influence of methylation on the intermediate EORTC score. 
Combining the intermediate EORTC risk score and methylation grade (Figure 5B) led to 
more accurate prediction of progression (P=0.007).  
 
Table 4: Progression-free survival analysis of clinicopathological and molecular factors. HR= Hazard Ratio; CI= 
Confidence Interval; * p<0.05. 
Variable Categorization Univariate  Multivariate 
  Patients Events p  HR 95% CI p 
Clinicopathological 
factors 
        
Age at diagnosis  <65 years 16 5 0.028*  103.1 3.1-
3401 
0.009* 
 ≥ 65 years 25 14      
Multiplicity Solitary 20 5 0.002*  12.3 0.91-
165 
0.058 
 Multiple 21 14      
Histological grade G1-G2 39 17 0.002*  0.08 0.001-
5.6 
0.244 
 G3 2 2      
Tumor size < 3 cm 23 11 0.672     
 ≥ 3 cm 13 5      
Previous 
recurrence 
No 32 11 0.003*  0.12 0.001-
2.17 
0.046* 
 Yes 9 8      
Adjacent CIS No 37 17 0.983     
 Yes 4 2      
Molecular factors         
TBX2 unmethylated 16 0 0.000*  13.44 0.69-
264 
0.08 
 methylated 18 14      
TBX3 unmethylated 31 10 0.000*  39.4 1.18-
1412 
0.044* 
 methylated 10 9      
GATA2 unmethylated 13 1 0.001*  34.6 1.41-
852 
0.03* 
 methylated 19 14      
ZIC4 unmethylated 24 8 0.003*  0.38 0.03-
3.84 
0.41 
 methylated 17 11      
 
  
Genome-wide analysis of CpG island methylation in bladder cancer 
 
71 
 
 
Figure 4: Methylation of speci c CGIs can predict progression to muscle-invasive disease in NMI pTa tumors. 
Patients without methylation of TBX2, GATA2, ZIC4, and TBX3, have a signi cantly better progression-free 
survival (A) Test set, GGMA assay. (B) Validation set. The di erences between the groups were signi cant as 
indicated (log-rank test). Green line indicates methylation, Blue line indicates no methylation and (+) 
indicates censored data. 
TBX2
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Table 5: Sensitivity, Specicity, Negative Predictive value and Positive Predictive value of prognostic markers 
for predicting progression. 
  Sensitivity Specicity Negative 
Predictive value 
Positive 
Predictive value 
AUC (p value) 
TBX2 100 80 100 78 0.96 (0.0001) 
TBX3 48 96 68 90 0.72 (0.019) 
GATA2 94 71 93 74 0.88 (0.0001) 
ZIC4 58 73 67 65 0.71 (0.021) 
 
 
Figure 5: Comparison of EORTC risk scores and methylation scores for predicting progression in the 
validation set (n=41) (A) Kaplan-Meier plot for progression-free survival according to the EORTC risk score. 
Based on these scores, patients score low, intermediate or high risk for progression (p=0.012) (B) Methylation 
grade improved prediction of progression in intermediate-risk EORTC group (p=0.007). Methylation grade 
was determined as (0-No gene methylated, 1-One gene methylated, 2- Two or more genes methylated). 
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Discussion 
The epigenetic progenitor model of cancer described by Feinberg [27] claims that cancer 
develops in three steps. The first being an epigenetic alteration of a stem or progenitor cell 
within a given tissue and the second a gate-keeper mutation followed by genetic and 
epigenetic instability leading to further tumor evolution. This hypothesis is supported by 
studies that showed that epigenetic alterations precede the initial mutations in cancer [28-
30]. Here, we report an investigation of BC associated aberrant DNA methylation. The 
genome-wide screening and subsequent GGMA validation assay allowed us to confirm 110 
CGIs that significantly differed in methylation in tumors when compared to urine-derived 
DNA from age-matched non-bladder cancer controls. These CGIs represent potential 
biomarkers for urine tests.  
We identified and validated four genes that are highly methylated in pTa tumors that later 
showed progression to MIBC. pTa tumors represent about 60% of all primary bladder 
tumors. Progression to MIBC in pTa tumors is much lower than for pT1 tumors, however, 
the risk is still 10% and 60-70% of patients will have on average 3 recurrences, warranting 
long-term surveillance [5-7]. We found that methylation of the TBX2, TBX3, GATA2 and ZIC4 
genes was significantly associated with progression. These genes encode transcription 
factors that are important in lineage decisions during development [31]. Gene expression 
profiling studies showed that all these genes are more expressed in NMIBC than in MIBC 
[32], which fits with our findings as we observed that these genes are more methylated in 
MIBC. TBX2 and TBX3 are transcriptional repressors that inhibit expression of the ARF gene 
a.o., thereby finally inhibiting P53 activation [33]. This may present an alternative for 
mutation of P53, which is frequent in MIBC. Mutations that reduce DNA binding of GATA2 
were discovered in familial myelodysplastic syndrome [34]. Currently prediction of 
progression in NMIBC is based on the progression scores developed by Sylvester [7], that 
have been taken up in the EAU guidelines. The markers described in this work enhanced 
the predictive accuracy of these risk scores and could thus contribute to a further objective 
stratification of patients. We previously showed that mutations in the FGFR3 gene are 
associated with a low chance of progression and combining the here identified markers 
with FGFR3 may also help to stratify patients presenting with pTa tumors for further clinical 
management, for instance, by increasing the number of follow-up visits for patients with 
methylation of the identified genes and lacking an FGFR3 mutation. An additional 
advantage is that both methylation and FGFR3 mutation analysis can be performed on 
DNA isolated from FFPE tissue, which is easier to obtain than fresh tissue. Other studies 
also reported prognostic markers based on genetic and epigenetic alterations that can be 
analysed on DNA isolated from FFPE tissue [24, 35]. Reinert et al showed methylation of 
TBX4 gene associated with progression in pTa tumors, while our study found methylation 
in TBX2 and TBX3 association with progression, this suggests the important role of T-box 
genes in BC progression [36]. Yates et al. identified a group of 5 genes that could 
significantly discriminate progressors from non-progressors in pTa and pT1 tumors 
combined. No multivariate analysis to compare the markers with clinical variables was 
performed. In the paper by Friedrich et al. methylation of TIMP3 also predicted progression 
in a set of patients with pTa and pT1 tumors, however, the marker was not compared to 
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other parameters. In conclusion, we present here validated easy-to-assay progression 
markers specific for pTa bladder tumors.   
Most genes discovered in the present study have never been shown to be methylated in 
BC or in other types of cancer. Some of the previously described methylated genes in 
bladder cancer are SOX9, CDKN2A, TERT, DAPK1, EDNRB, DBC1, NID2, TWIST1, LAMB3, GDF15, 
TMEFF2, VIM, MYO3A, CA10, SOX11, and NKX6-2. Most of these were also found to be 
methylated in our study, although only SOX9 and CDKN2A made it to the list of our 96 
highly methylated CGIs [37-40]. A recent study by Reinert et al showed that a panel of 8 
markers are methylated in BC, our study also found 3 of these markers representing 
HOXA9, POU4F2, PCDHGA12 to be higly methylated in BC [36]. We observed that NMIBCs 
with a wild-type FGFR3 gene have more methylated CGIs and the intensity of methylation 
is more profound than in the FGFR3 mutant NMIBC and MIBC groups. Interestingly  similar 
results were recently described by Serizawa et al [41]. The difference in methylation 
presents additional evidence that the two subgroups of NMIBC develop along different 
pathogenesis pathways. The extensive methylation in WT NMIBC is reminiscent of the CpG 
island methylator phenotype (CIMP) in colorectal cancers (CRC) and gliomas [42-45]. When 
comparing the genes methylated in this study with those found by us, there was hardly 
any overlap. This confirms that CGI methylation is tissue and tumour type specific [46].   
In line with previous reports in solid tumors [25, 26, 47], a high proportion of the genes we 
find de novo methylated in BC are repressed by polycomb complexes in embryonic stem 
cells. PcG target genes are as much as 12 times as likely to be silenced by DNA methylation 
in cancer as non-PcG target genes. Our findings confirm those of Wolff et al, where they 
showed 40% methylated genes in BC as PcG targets [48]. These findings strongly suggest 
that methylation occurs early in bladder cancer development.  
 
Conclusions 
We have identified four methylation markers that predict progression in pTa tumors 
thereby allowing stratification of patients for personalized follow-up. In addition, we 
identified 110 CGIs as putative biomarkers for early detection of BC in voided urine.  
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Abstract  
 
Background 
Aberrant DNA methylation is associated with the pathogenesis of bladder cancer (BC) and 
can serve as a diagnostic biomarker. 
 
Objective 
To develop a sensitive urine assay for the diagnosis of recurrent bladder tumours in 
patients with a previous primary non-muscle invasive BC (NMIBC) G1/G2. 
 
Design, setting, and participants 
We selected eight CpG islands (CGIs) methylated in BC. Sensitivity of the CGIs for 
recurrences detection was investigated on a test set of 101 preTUR (before Trans Urethral 
Resection) urines using a bisulfite specific single nucleotide primer extension assay (BS-
SNaPshot). Specificity was determined on 70 urines from healthy males >50 years. A 3-plex 
assay for the best combination was developed and validated on an independent set of 95 
preTUR urines, 39 urines associated with a primary G1/G2 tumour and 40 urines from 
patients who were recurrence free for at least 6 months. 
 
Outcome measurements and statistical analysis 
ROC curves were used to predict the best single marker and binary logistic regression was 
performed to select the best combination. 
 
Results and limitations 
The 3-plex assay identified recurrent BC in voided urine with a sensitivity of 74% in the 
validation set (specificity of 90%). Sensitivity for the detection of primary G1/G2 tumours 
was 80%. Combining the methylation assay with the FGFR3 (fibroblast growth factor 
receptor 3) mutation assay resulted in a sensitivity of 79%. The 3-plex methylation assay 
was more sensitive than cytology and the FGFR3 assay. There were 22% false positives in 
patients that were recurrence free for >6 months. 
 
Conclusion 
The combination of the methylation and FGFR3 assays efficiently detects recurrent BC 
without the need for stratification of patients regarding methylation/mutation status of 
the primary tumour. We conclude that sensitivity of this combination is in the same range 
as white light cystoscopy and we suggest that, a subsequent study should be performed 
investigating a modified surveillance protocol consisting of the urine test followed by 
cystoscopy only when the urine test is positive, for patients in the low/intermediate risk 
group. 
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Introduction 
BC is the fifth most common cancer in the western world with an estimated 386,300 new 
cases and 150,200 deaths in the year 2008 worldwide [1]. Most bladder tumours (70-80%) 
are non-muscle-invasive (NMIBC) at presentation and patients have a good prognosis [2]. 
NMIBC comprises stages pTa, pT1 and pTis. Unfortunately, 70% of patients with NMIBC will 
have recurrence after transurethral resection (TUR) and 10-20% of patients will eventually 
have progression to muscle-invasive BC (MIBC) [3-5]. As a consequence, patients are 
monitored by cystoscopy every 3-12 months after TUR, making BC one of the most 
expensive cancers to treat [6]. Currently cystoscopy is the gold standard for surveillance, 
however, it is an invasive and uncomfortable procedure [7, 8]. Moreover with cystoscopy, 
there is 20 to 30% chance to miss a tumour [9, 10]. 
Cytological examination of voided urine can identify tumour cells with a high sensitivity if 
a high-grade tumour is present [11]. However, for low stage and grade tumours the 
sensitivity is low. This low sensitivity induced the development of urine-based assays in the 
past decade. Although some assays have been approved by the FDA, they have so far not 
been taken up in routine clinical practice [12-16]. In most studies the sensitivity of the 
markers was assessed on a convenience set of urines that comprises urines from primary 
and recurrent tumours and urines from patients with high stage and grade tumours. 
Hence when tested on urines from patients under surveillance the sensitivity of these 
markers is disappointing [14, 17]. Because of these problems our group has specifically 
focused on markers that are better in detecting recurrent BC in patients who presented 
with a primary NMIBC [18-20]. Up to 80% of the pTa tumours have a mutation in the 
fibroblast growth factor receptor 3 (FGFR3) oncogene [21-23]. We showed that a multiplex 
assay for the most common mutations was able to detect about 75% of tumours smaller 
than 1.5 cm and 100% if the tumours were larger than 3 cm [24, 25]. A great advantage of 
the FGFR3 assay is that since these mutations are extremely rare in normal cells, an assay to 
detect FGFR3 mutations has a specificity of 100%. A disadvantage is that the patients need 
to be stratified up front for the presence of an FGFR3 mutation and therefore other assays 
are required for patients with wild-type tumours. 
It is evident from many studies that methylated CpG islands (CGIs) may present useful 
biomarkers. In order to find the most promising CGIs for BC prognosis and diagnosis we 
have previously performed a genome-wide study [26]. In the current study, we 
investigated selected CGIs for the detection of recurrent BC in voided urine. 
 
Materials and methods 
Bladder cancer patient samples and other control samples 
Forty-eight FFPE BC DNAs from a mixture of primary and recurrent tumours, 101 pre-TUR 
urines (test set) from patients with a previous primary NMIBC G1/G2, 70 urines from males 
(> 50 years of age) without any history of BC as controls containing 20 urines with a high 
leucocyte count, 39 preTUR urines from primary tumours (pTaG1 and pTaG2), and 40 
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urines were collected during surveillance in a period in which no recurrences occurred 
within 6 months in the Departments of Pathology and Urology, Erasmus MC.  Out of these 
40 patients, 24 are under and 16 are over 65 years. There were 27 males and 13 females. 
The median follow-up was 24 months. These patient samples were used according to “The 
Code for Proper Secondary Use of Human Tissues in the Netherlands” 
(http://www.federa.org/). An additional set of 95 pre-TUR urines (validation set) from 
patients with a previous primary NMIBC G1/G2 was obtained from Aarhus University 
Hospital, Denmark . The test and validation set urines were collected before transurethral 
resection of the corresponding recurrent tumour. With 70 controls and 95 validation 
samples we have 90% power to detect 20% difference in methylation. Patient 
characteristics are presented in Table 1. There is no overlap of the samples used. Urine 
samples (25-100 ml) were collected one day before TUR and stored at 4 °C. Within 6 hrs 
after voiding, samples were centrifuged at 4000 rpm for 10 minutes, followed by washing 
the pellet twice with cold PBS, then stored at -20 °C for DNA isolation. DNA was isolated 
using DNeasy Tissue kit (Qiagen GmbH, Hilden, Germany). Recurrences were registered 
only when proven by histology. The study adhered to the STARD guidelines for the 
reporting of studies of diagnostic accuracy [27]. 
 
Table 1: Patient characteristics 
Characteristics Test set Urines 
(n=101) 
Validation set 
Urines (n=95) 
Primary 
Tumour Urines 
(n=39) 
FFPE 
tumours 
(n=48) 
Gender      
Male 78 52 29 39 
Female 23 43 10 9 
Age      
<65 38 36 17 15 
>65 63 59 22 33 
Stage      
Ta 73 93 39 39 
T1 13 0 0 8 
>=T2 14 1 0 1 
NA 1 1 0 0 
Grade      
G1 23 33 16 15 
G2 46 52 23 25 
G3 27 9 0 2 
NA 5 1 0 0 
FGFR3      
Mutant 10 49 15 39 
Wild type 91 46 24 9 
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Bisulfite conversion and BS-SNaPshot assay 
Bisulfite conversion and quantitative assessment of methylation was done as described 
previously [26]. In short: DNA was converted with sodium bisulfite (EZ DNA methylation 
gold kit, Zymo Research Corp, Orange, CA, USA). PCR of selected CGIs was performed using 
20 ng of converted DNA, 20 pmols of primers and 10 µL of KAPA2G Robust HotStart 
ReadyMix (Kapa Biosystems, USA) in a total volume of 20 µl. The PCR products were treated 
with 2 units of Exonuclease I (ExoI) and 3 units of Shrimp Alkaline Phosphatase (SAP) (USB, 
Cleveland, Ohio USA). This was followed by a single-nucleotide probe extension assay 
using a SNaPshot Multiplex kit (Applied Biosystems, Foster City, CA) and probes designed 
to anneal to either the forward or reverse strand adjacent to the investigating CpG site. 
These probes were fitted with T-tails of different length at their 5’ ends to allow separation 
of the extension products by size [22, 25]. The single nucleotide primer extension reactions 
were performed in a total volume of 10 µl containing 2 µl SAP/ExoI treated PCR product, 
2.5 µl SNaPshot Multiplex Ready Reaction mix, 1 x Big Dye sequencing buffer, and 1 µl 
probe mix. Thermal cycler conditions were: 25 cycles of 10 seconds at 95˚C, 5 seconds at 
50˚C, and 30 seconds at 60˚C. The products were treated with 1 unit SAP at 37°C for 60 min, 
and at 75°C for 15 min, and were analyzed on an automatic sequencer (ABI PRISM 3130 XL 
Genetic Analyzer, Applied Biosystems) with the fluorescent label on the incorporated 
ddNTP indicating incorporation of a C or T or an A or G depending on the strand 
investigated. The primers and probes of 8 CGI markers are given in Supplementary Table 
S1. We further developed a multiplex BS-SNaPshot assay aimed at detecting the 
methylation status of the three most interesting CGIs (OTX1, ONECUT2 and OSR1) in a single 
PCR and a single nucleotide primer extension reaction. Concentrations of primers and 
probes for this assay are given in Supplementary Table S1. A typical multiplex assay is 
shown in the Figure 4. 
 
FGFR3 mutation analysis 
FGFR3 mutation analysis was performed as described previously [25]. Briefly, we performed 
a multiplex polymerase chain reaction (PCR) of the 3 exons containing the most common 
FGFR3 mutations (exons 7, 10 and 15). Subsequently we performed single nucleotide 
polymorphism analysis using primers that anneal to the PCR product adjacent to the 
mutation site. Mutation probes were extended with a labeled dideoxynucleotide and 
products were analyzed on an ABI PRISM® 3100 Genetic Analyzer with the label indicating 
the presence or absence of a mutation. GeneScan® Analysis Software, version 3.7 was used 
for data analysis. Primers and probes are given in Supplementary Table S1. 
 
Statistical analysis 
For the analysis of BS-SNaPshot data, we used GeneMarker Software version 1.7 
(SoftGenetics, State College, PA, USA). The methylation percentage for each gene and each 
sample was calculated as the ratio of the height of the C/G peak divided by the height of 
the C/G peak plus T/A peak multiplied by 100. We calculated the sensitivity and specificity 
Chapter 4 
84 
 
of the different combinations of the 8 markers by plotting the receiver operating 
characteristic curve (ROC) and calculating the area under the curve (AUC) using SPSS 
statistical software V17.0. To predict the best combination of markers, we performed a 
binary logistic regression on all possible combinations of the markers. Binary logistic 
regression will assign a beta (Coefficient) value for each marker based on the contribution 
in predicting an outcome. From these beta values we calculated the predictive probability 
value for that particular combination in all individual samples investigated using a formula
ze−+1
1 , where z = constant + % methylation marker A * β value marker A + % methylation 
marker B * β value marker B etc. We chose a cut-off value allowing 10% false positives in 
the control group (specificity=90%). From this analysis we picked the best 3-marker 
combination that showed the highest sensitivity.  
 
Results 
Identification and validation of methylated CGIs in BC 
Study design is described in Figure 1. Patient characteristics for all cohorts are given in 
Table 1. Previously we identified 110 CGIs methylated in BC but not in control urine [26] 
(PCT(NL2010)/050213). For this study the 21 CGIs with the largest methylation difference 
were selected. First we tested the performance of 42 CpGs from these 21 CGIs in BS-
SNaPshot assays on DNA obtained from BC cell lines (results not shown). We selected 8 
candidate CpGs that performed best regarding PCR efficiency and probe signal. We then 
validated the methylation status of these eight CpGs in an independent set of 48 bladder 
tumours and 70 normal urines. Figure 2 shows the methylation % of the 8 markers. 
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Figure 1: Study design. 
  
Genome-wide analysis of DNA-
methylation using Agilent 244k    
Human CpG island Microarray 
 (n=44 tumors) 
Results: Validated 110 CGI’s 
methylated in bladder tumours, but 
not in the normal urines from age 
matched controls 
(Kandimalla et al., Eur Urol. 2012) 
Results: Discovered 392 CGI’s 
methylated in bladder tumours 
Validation 
Discovery 
The 3 gene methylation panel was 
validated in an independent set of 95 
preTUR urines from recurrent tumours 
(Validation set) 
Results: Methylation assay consisting of a 
combination of 3 markers showed a 
sensitivity of 74% at 90% specificity in the 
validation set 
Results: Combination of the methylation 
assay with the FGFR3 assay resulted in a 
sensitivity of 79% in the detection of 
recurrent bladder tumours in voided 
Marker Selection 
Analysis of 8 best CGI’s in an independent 
set of 48 FFPE tumors, 70 urines from 
healthy individuals, 40 urines from patients 
without recurrence and 101 preTUR urines 
from recurrent tumours (Test set)  
Results: A 3 gene methylation panel 
showed a sensitivity of 68% in the test set 
at 90% specificity 
Validation 
Analysis of 238 CGI’s with a custom 
Illumina 384-plex Golden Gate  
Methylation Assay (n=77 tumours) 
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Selection of the optimal combination of markers for the detection of recurrent BC in 
voided urine 
The eight markers were then analyzed on a test set of 101 voided urines collected from 
different patients before resection of a recurrent tumour. We calculated the power of each 
methylation marker by calculating the AUC using the 101 recurrent urines against the 70 
control samples. Specificity was set at 90%. The best single marker in the test set was OTX1 
with a sensitivity of 65%. Performance of the 8 markers on the test set is shown in Table 2 
and Figure 2. The p-values in Table 2 indicate that the markers are significantly different 
between urines from patient and healthy individuals. In addition we analyzed sensitivity of 
each marker regarding detection of different stage and grade recurrences. Sensitivity 
increased with stage and grade as shown in Table 3. 
 
Table 2: Sensitivity, PPV, NPV and AUC of the individual markers in the test set (n=101). Specificity is 90%).The 
combination of OTX1, ONECUT2 and OSR1 was found to be the most sensitive combination of markers 
Gene Sensitivity PPV NPV AUC 95% CI-Lower 95% CI-Upper P-value 
OTX1 65 (65/101) 90 65 .805 .740 .871 .000 
MEIS1 46 (46/101) 87 54 .749 .678 .821 .000 
ONECUT2 52 (52/101) 88 57 .737 .664 .810 .000 
SIM2 49 (49/101) 88 56 .753 .683 .824 .000 
FOXA1 38 (38/101) 84 50 .659 .579 .739 .000 
ZNF503 52 (52/101) 88 57 .784 .717 .852 .000 
HOXA9 62 (62/101) 90 63 .829 .770 .888 .000 
OSR1 44 (44/101) 86 53 .705 .630 .781 .000 
OTX1+ONECUT2+OSR1 68 (68/101) 91 67 .801 .734 .867 .000 
 
Table 3: Sensitivity of the methylation markers for detection of different stage and grade recurrences in the 
test set (n=101). Specificity of the markers is 90%. 
Gene/Combination Ta (n=73) T1 (n=13) T2 (n=14) G1 
(n=23) 
G2 
(n=46) 
G3 
(n=27) 
OTX1 60 (44/73) 77 (10/13) 86 (12/14) 48 (11/23) 63 (29/46) 81 (22/27) 
MEIS1 44 (32/73) 62 (8/13) 50 (7/14) 30 (7/23) 48 (22/46) 59 (16/27) 
ONECUT2 49 (36/73) 77 (10/13) 50 (7/14) 43 (10/23) 46 (21/46) 70 (19/27) 
SIM2 40 (29/73) 85 (11/13) 71 (10/14) 22 (5/23) 46 (21/46) 78 (21/27) 
FOXA1 33 (24/73) 62 (8/13) 43 (6/14) 4 (1/23) 43 (20/46) 59 (16/27) 
ZNF503 47 (34/73) 77 (10/13) 64 (9/14) 35 (8/23) 50 (23/46) 70 (19/27) 
HOXA9 60 (44/73) 77 (10/13) 64 (9/14) 52 (12/23) 61 (28/46) 78 (21/27) 
OSR1 37 (27/73) 69 (9/13) 57 (8/14) 17 (4/23) 37 (17/46) 74 (20/27) 
OTX1_ONECUT2_OSR1 64 (47/73) 77 (10/13) 86 (12/14) 57 (13/23) 65 (30/46) 81 (22/27) 
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Figure 2: Scatter plots of methylation percentage of each marker in the samples investigated. A) Urines from 
healthy individuals (n=70) B) Urines from patients without recurrence (n=40) C) Tumour tissue (n=48) D) Test 
set urines (n=101). 
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A 3-plex sensitive and reproducible methylation assay 
Next we performed a binary logistic regression with all possible combinations and picked 
the combination of three CGIs (in the OTX1, ONECUT2 and OSR1 genes) with the highest 
sensitivity. The predictive probability value was calculated using the following formula: z = 
-1.618 + % methylation OTX1 * 0.168 + % methylation ONECUT2 * 0.050 + % methylation 
OSR1 * 0.016. A predictive probability cut-o value of 0.580 was chosen, allowing 10% false 
positives in the normal urines, which is shown in Figure 3. This resulted in a sensitivity of 
68% in the test set. Sensitivity, AUC, PPV, NPV of this combination are presented in Table 2. 
The 3 markers were subsequently combined in a 3-plex BS-SNaPshot assay as depicted in 
Figure 4. The 3-plex methylation assay showed sensitivities of 64, 77 and 86% for Ta, T1 
and T2 recurrences, respectively and 57, 65 and 81% for detecting G1, G2 and G3 tumours 
(Table 3). Reproducibility of the assay was investigated independently by two investigators 
on 16 urine samples. Percentages of methylation were highly correlated (Supplementary 
Figure 1).  In order to get an impression of methylation in the case of multiple 
metachronous tumours, we selected patients with multiple tumours (30 tumours from 11 
patients) from the original validation array [26]). Methylation of the 3 genes was highly 
consistent within a patient (Supplementary Table 2). 
 
 
Figure 3: Predictive Probability Value plot of the 3-plex methylation assay. The chosen cut-o was 0.58. 
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Figure 4: Multiplex Methylation Assay. The gure shows a typical ABI Sequencer output le analyzed by the 
GeneMarker Software. An analysis of tumour tissue, preTUR urine and normal urine is shown in top, middle 
and bottom panels, respectively. Peaks labeled with. C or G represent the methylated nucleotide and T or A 
the not methylated nucleotide. 
Validation of the best combination of markers in an independent set of urines 
Subsequently, the 3-plex assay was tested on an independent validation set of 95 preTUR 
urines from patients with a previous NMIBC G1/G2. The best single marker in the test set 
OTX1 also showed the highest sensitivity (72%) in the validation set. The 3-plex assay had a 
sensitivity of 74% with an AUC of 0.86 (Table 4, Figure 5). We achieved a sensitivity of 80% 
for the detection of primary NMIBC G1/G2 tumours. We further observed 22% false 
positives in 40 urines investigated from BC patients who did not have a recurrence 6 
months following urine collection (Figure 2 and 3). 
Next we combined the 3-gene methylation panel with FGFR3 status of the preTUR urine. 
This lead to an increase of 5% sensitivity in the validation set achieving 79% sensitivity with 
an AUC of 0.89 for the detection of recurrent BC in voided urine (Table 4). The p-values in 
Table 4 indicate that the markers/assays are signicantly dierent between urines from 
patient and healthy individuals. The AUC curve for the combination of the methylation and 
the FGFR3 assay is shown in Figure 5. The data of cytology, FGFR3 and methylation was 
available for 72 urines. For this set of urines we calculated the sensitivity, PPV, NPV and 
AUC of cytology alone, methylation+cytology and methylation+cytology+FGFR3. Results 
are shown in Table 4.  
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Table 4: Validation of 3-plex methylation assay in an independent set of 95 preTUR urines (validation set, 
n=95) alone and in combination with the FGFR3 assay and cytology. Specicity of 3-plex assay, 3-plex assay 
plus FGFR3 assay, 3-plex assay plus cytology and 3-plex assay together with cytology and FGFR3 is 90%, 
while it is 100% for the FGFR3 assay and cytology. 
Assay Sensitivity PPV NPV AUC 95% CI-
Lower 
95% CI-
Upper 
P-
value 
Methylation (OTX1+ONECUT2+OSR1) 74 91 72 .864 .808 .919 .000 
FGFR3 52 100 58 .762 .692 .832 .000 
Methylation + FGFR3 79 92 76 .886 .835 .938 .000 
Cytology 57 100 70 .785 .707 .863 .000 
Methylation + Cytology 77 89 79 .890 .833 .947 .000 
Methylation + Cytology + FGFR3 82 89 83 .904 .850 .959 .000 
 
Figure 5: ROC curve of methylation assay (dotted line) and methylation + FGFR3 assay (thick line) for the 
validation set. 
The 3-plex methylation assay is more sensitive than the FGFR3 and cytology 
Next, we compared the 3-plex methylation assay with the FGFR3 assay and cytology in the 
validation set. Methylation, FGFR3 mutation status and cytology information was available 
for 72 urine samples. The methylation assay showed a sensitivity of 74%, while it was 57% 
for cytology and 52% for FGFR3, respectively. When we split this group according to grade, 
the sensitivity increased from low to high grade as shown in Table 5. The sensitivities of the 
combinations Methylation + FGFR3, Methylation + Cytology and Methylation + FGFR3 + 
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Cytology were 79, 77 and 82%, respectively. These results show that the methylation assay 
is more sensitive than cytology and the FGFR3 assay (when patients were not stratified 
based on the FGFR3 or methylation status of their primary tumour). 
 
Table 5: Comparison of the sensitivities of the methylation assay, FGFR3 and cytology and sensitivities of the 
various combinations (validation set, n=95). 
Assay G1 (n=33) G2 (n=52) G3 (n=9) Overall (n=94) 
Methylation 67 (22/33) 77 (40/52) 78 (7/9) 74 (70/94) 
FGFR3 60 (20/33) 48 (25/52) 56 (5/9) 52 (49/94) 
Cytology 36 (9/25) 67 (26/39) 75 (6/8) 57 (41/72) 
Methylation + FGFR3 73 (24/33) 81 (42/52) 78 (7/9) 79 (74/94) 
Methylation+ Cytology 68 (17/25) 82 (32/39) 87 (7/8) 77 (55/72) 
Methylation+FGFR3+Cytology 72 (18/25) 87 (34/39) 88 (7/8) 82 (59/72) 
 
Discussion 
A major problem in the management of patients presenting with NMIBC is that 70% will 
develop one or more recurrences and that recurrences can keep on developing for up to 
25 years [6]. Surveillance of these patients by cystoscopy is warranted [28]. However, 
cystoscopy is an invasive diagnostic procedure that is not well tolerated by many patients. 
Cytology has a high sensitivity for high-grade lesions, but lacks sensitivity for low-grade 
tumours [14]. To provide an alternative for cystoscopy and cytology, the development of 
molecular non-invasive tests using voided urine has been a major undertaking in the last 
decade. However, what is still lacking are tests that address the patient population in 
question, i.e. patients under surveillance for potential recurrences after a primary G1/G2 
NMIBC. One-third of these patients do not develop recurrences at all and low/intermediate 
risk patients may develop only few recurrences over a long period of time. Hence, 
surveillance by too frequent cystoscopies can be considered as overtreatment of many of 
these patients. An ideal test for surveillance of BC that can replace cystoscopy should be 
urine based, sensitive, cost-effective, easy to perform with limited material, and with no 
intra observer variability. 
To achieve this, we developed a 3-plex assay for the diagnosis of recurrent BC. To our 
knowledge this is the first study, where the methylation markers were assessed during 
follow-up of patients with a primary Ta/T1G1/G2 tumour. Our three gene methylation 
panel consisting of OTX1, ONECUT2 and OSR1 had a sensitivity of 68 and 74% in the test 
and validation set respectively with a specificity of 90% for the detection of recurrent 
bladder tumours in voided urine. Previously we and Serizawa et al., [29] showed an inverse 
correlation between FGFR3 mutation and methylation, therefore a combination of these 
assays could increase sensitivity for the detection of recurrent BC. We therefore combined 
the 3-plex methylation assay with the FGFR3 mutation assay. The combination of both 
assays increased sensitivity to 79% in the validation set. 
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It is our experience that many urine samples contain low amounts of cells and a yield of 50 
nanogram DNA from 50 ml of urine is no exception. The FGFR3 and 3-plex assays require 5 
and 30 nanogram DNA each. Hence, there will be sufficient DNA in most urine samples to 
perform these assays.  Both assays are easy to perform in a standard molecular diagnostic 
laboratory. Moreover, we have shown that they are highly reproducible between different 
operators. Combined material costs of the two assays, including DNA isolation, amount to 
about 30€. Personnel costs depend on the number of assayed samples, being cheaper 
when many samples are analyzed simultaneously. 
The fact that not all recurrences are detected with the urine assays is most probably due to 
the absence or low concentration of tumour cells in the urine sample. This could probably 
be improved by analyzing more than one urine sample as we showed previously for the 
FGFR3 mutation assay [24]. Another possibility would be to increase the analytical 
sensitivity of the assays. For the FGFR3 assay we obtained an analytical sensitivity of about 
5% (the mutation is detected when more than 5% of the cells harbor the mutation [25]). 
For the similar 3-plex methylation assay this would be the same. Higher analytical 
sensitivity can possibly be obtained by using next-generation sequencing (NGS). However, 
at the moment the costs of methylation+FGFR3 as performed in this work is still much 
cheaper. We further observed that multiple tumours from a patient have highly 
concordant methylation of the 3 markers, which underlines the usefulness of the markers 
for surveillance. The sensitivity of our assay combination is similar to the sensitivity of the 
current gold standard white light cystoscopy with sensitivity in the range of 68 to 83% 
when compared to the more sensitive blue light cystoscopy [30, 31]. Given the comparable 
sensitivities of urine testing and cystoscopy, we suggest that, a subsequent study should 
be performed investigating a modified surveillance protocol consisting of the urine test 
followed by cystoscopy, only when the urine test is positive, for patients in the 
low/intermediate risk BC group.  
A number of recent studies have reported high sensitivities with DNA methylation 
biomarkers for the detection of BC in voided urine [32-43]. Three of these studies used 
methylation specific PCR (MSP) and reported sensitivities in the range of 85 to 94% at a 
specificity in the range of 93 to 100%. Renard et al showed a high sensitivity for the 
combination of the TWIST1 and NID2 genes for the diagnosis of primary BC. Reinert and 
colleagues used a methylation sensitive high resolution melting analysis and reported 84% 
sensitivity at 96% specificity. The study by Zuiverloon [44] et al., reported a four gene 
methylation panel to detect recurrent bladder tumours with a sensitivity of 72% at a 
specificity of 55%. However, all these studies, with the exception of Zuiverloon et al, used 
urines from patients with primary and recurrent tumours, including high-grade and MIBC. 
Hence the detection rate of recurrent tumours developing after a primary NMIBC G1/G2 
using these markers is probably much lower. The CGIs found by others to be methylated in 
BC were largely also found to be methylated in our genome-wide study, but to a lesser 
extent than the ones we chose for our diagnostic assay. 
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The OTX1 (orthodenticle homeobox 1) gene is methylated in lung cancer [45] and its 
expression is regulated by p53 in breast cancer [46]. The OSR1 (odd-skipped related 1) 
gene is methylated in lung and breast cancer [45, 47]. The ONECUT2 (one cut homeobox 2) 
gene participates in the network of transcription factors regulating liver differentiation and 
metabolism [48]. This gene is methylated in lymphomas and lung cancer [49, 50].  The 
methylation of these genes in BC was not reported before. 
 
Conclusion 
Here we report a genome-wide methylation investigation in BC, followed by a selection 
and validation strategy to develop a 3-plex methylation assay specific for the detection of 
recurrent BC. The combination of the 3-plex methylation assay and the FGFR3 assay 
efficiently detects recurrent BC without the need for up-front stratification of patients. 
Given the comparable sensitivities of urine testing and cystoscopy, we suggest that, a 
subsequent study should be performed investigating a modified surveillance protocol 
consisting of the urine test followed by cystoscopy, only when the urine test is positive, for 
patients in the low/intermediate risk BC group. 
Further validation of the presented markers in a prospective longitudinal study is 
underway. 
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Supplementary Figure 1: Consistency of methylation assay 
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Supplementary Table 1: Primers and probes used for the BS-SNaPshot assay. 
 Marker Primer/Probe Sequence Concentration pmol 
Single-plex Methylation Assays  
  HOXA9 Forward primer 5'-TTGGGGAAAAAATTATAAGTGG-3' 10 
   Reverse primer 5'-AATTTCCAACCCTAACCTTAAAC-3' 10 
   Amplicon size 270 bp   
   SNaPshot probe 5'-TTTYGTTTTGGTTATTTA-3' 2 
  ONECUT2  Forward primer 5'-GGGGTTTTTTGTTTTTTGTATTTTT-3' 10 
   Reverse primer 5'-TCATTTTCAAACTTAAACTTAATCACC-3' 10 
   Amplicon size 206 bp   
   SNaPshot probe 5'-GTTTGGGYGGTTGGGTT-3' 2 
  FOXA1  Forward primer 5'-TTAGGTAGGTAGAAGTAGAGGGAGA-3' 10 
   Reverse primer 5'-AAAAAAAACCCTAAAAAAACTC-3' 10 
   Amplicon size 204 bp   
   SNaPshot probe 5'-TGGTAGATAGTAGGGTTTGGGT-3' 2 
  SIM2 Forward primer 5'-GGTTTTTGTTGATTTTTAGGTTA-3' 10 
   Reverse primer 5'-ACCTCTTCCAAAAATACAACTTTC-3' 10 
   Amplicon size 171 bp   
   SNaPshot probe 5'-GTTAAGGTAAGGAATTGTTTTG-3' 2 
  MEIS1 Forward primer 5'-GGGTTTTTAGAGGTTAGGGGAA-3' 10 
   Reverse primer 5'-CAACTAAATAACCAAACCTCTCCTC-3' 10 
   Amplicon size 256 bp   
   SNaPshot probe 5'-GGAGAGGGGGGTTATGATGTTAGG-3' 2 
  OSR1 Forward primer 5'-GTTTTTTTAGTAGAGATTAGGTTTTTAGTT-3' 10 
   Reverse primer 5'-TAAAAACTACTCAATTTTCACTCC-3' 10 
   Amplicon size 297 bp   
   SNaPshot probe 5'-TTAAATTTTAGTTTTTTTTT-3' 2 
  ZNF503  Forward primer 5'-GTTTGTGTTTGGAGAATTTTTAGAG-3' 10 
   Reverse primer 5'-AAACTACCTCCTCCCCAATTTAAT-3' 10 
   Amplicon size 263 bp   
   SNaPshot probe 5'-TTGGGTGATTTAGTTTGGTT-3' 2 
  OTX1  Forward primer 5'-TTTTGAGAGGTATAGAGAGGGGTAGT-3' 10 
   Reverse primer 5'-CCCCTAACAAACCCAAATCTC-3' 10 
   Amplicon size 172 bp   
    SNaPshot probe 5'-TTTATTTGTGGTTTTTTAGGTT-3' 2 
Multiplex Methylation Assay   
  OTX1  Forward primer 5'-TTTTGAGAGGTATAGAGAGGGGTAGT-3' 10 
   Reverse primer 5'-CCCCTAACAAACCCAAATCTC-3' 10 
   Amplicon size 172 bp   
   SNaPshot probe 5'-TTTATTTGTGGTTTTTTAGGTT-3' 5 
  ONECUT2  Forward primer 5'-GGGGTTTTTTGTTTTTTGTATTTTT-3' 10 
   Reverse primer 5'-TCATTTTCAAACTTAAACTTAATCACC-3' 10 
   Amplicon size 206 bp   
   SNaPshot probe 5'-GTTTGGGYGGTTGGGTT-3' 5 
  OSR1 Forward primer 5'-GTTTTTTTAGTAGAGATTAGGTTTTTAGTT-3' 10 
   Reverse primer 5'-TAAAAACTACTCAATTTTCACTCC-3' 10 
   Amplicon size 297 bp   
    SNaPshot probe 5'-TTAAATTTTAGTTTTTTTTT-3' 10 
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FGFR3 Assay   
  Exon 7 Forward primer 5’- AGTGGCGGTGGTGGTGAGGGAG 3’ 18 
   Reverse primer 5’- GCACCGCCGTCTGGTTGG 3’ 18 
  Exon 10 Forward primer 5’- CAACGCCCATGTCTTTGCAG 3’ 7.5 
   Reverse primer 5’- AGGCGGCAGAGCGTCACAG 3’ 7.5 
  Exon 15 Forward primer 5’- GACCGAGGACAACGTGATG 3’ 10 
   Reverse primer 5’- GTGTGGGAAGGCGGTGTTG 3’ 10 
  R248C  SNaPshot probe 5'-T46CGTCATCTGCCCCCACAGAG  2 
  S249C  SNaPshot probe 5'-T36TCTGCCCCCACAGAGCGCT 2.4 
  G372C  SNaPshot probe 5'-T29GGTGGAGGCTGACGAGGCG 0.4 
  S373C  SNaPshot probe 5'-T19GAGGATGCCTGCATACACAC 1 
  Y375C  SNaPshot probe 5'-T43ACGAGGCGGGCAGTGTGT 0.6 
  G382R  SNaPshot probe 5'-T56GAACAGGAAGAAGCCCACCC 0.6 
  A393E  SNaPshot probe 5'-T34CCTGTTCATCCTGGTGGTGG 2.4 
  K652M/T  SNaPshot probe 5'-T20CACAACCTCGACTACTACAAGA 0.8 
  K652E/Q  SNaPshot probe 5'-T50GCACAACCTCGACTACTACAAG 1.2 
  
Chapter 4 
100 
 
Supplementary Table 2: Methylation in multiple metachronous tumours. Predictive probability value was 
calculated for all metachronous tumours using the formula specified in the methods and results section. The 
cut-off chosen was 0.58. The table shows that all metachronous tumors are detected and moreover the PPVs 
are highly correlated. Methylation Beta value range is 0 to 1; 0 represents no methylation and 1 represents 
100% methylation. 
   Methylation Beta value   
Patient Tumour ID ONECUT2 OSR1 OTX1 PPV 
Patient 1 Ta:70 0.77 0.11 0.67 1.00 
Patient 1 Ta:77 0.44 0.11 0.71 1.00 
Patient 1 Ta:73 0.46 0.07 0.54 1.00 
Patient 1 Ta:17 0.68 0.22 0.68 1.00 
Patient 2 Ta:71 0.43 0.31 0.46 1.00 
Patient 2 Ta:19 0.60 0.21 0.59 1.00 
Patient 3 Ta:8 0.43 0.78 0.33 1.00 
Patient 3 Ta:79 0.49 0.73 0.61 1.00 
Patient 4 Ta:3 0.53 0.85 0.46 1.00 
Patient 4 Ta:1 0.18 0.57 0.32 1.00 
Patient 4 Ta:42 0.69 0.44 0.52 1.00 
Patient 4 Ta:2 0.33 0.49 0.35 1.00 
Patient 5 T1:20 0.97 0.68 0.02 0.99 
Patient 5 T2:16 0.83 0.54 0.81 1.00 
Patient 6 Ta:4 0.69 0.78 0.75 1.00 
Patient 6 T1:15 0.84 0.91 0.86 1.00 
Patient 6 T1:32 0.92 0.87 0.34 1.00 
Patient 7 Ta:72 0.33 0.19 0.07 0.82 
Patient 7 Ta:74 0.35 0.35 0.11 0.93 
Patient 7 T1:24 0.55 0.08 0.15 0.98 
Patient 8 T2:38 0.24 0.82 0.80 1.00 
Patient 8 T2:48 0.32 0.79 0.69 1.00 
Patient 9 T1:11 0.82 0.84 0.77 1.00 
Patient 9 T1:10 0.84 0.75 0.84 1.00 
Patient 10 T2:43 0.81 0.66 0.80 1.00 
Patient 10 T2:45 0.75 0.80 0.75 1.00 
Patient 10 T2:66 0.48 0.65 0.16 0.99 
Patient 10 T2:69 0.68 0.73 0.74 1.00 
Patient 11 T2:83 0.54 0.74 0.76 1.00 
Patient 11 T2:88 0.34 0.48 0.77 1.00 
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Abstract  
Aberrant DNA methylation leads to gene silencing and is associated with the pathogenesis 
of bladder cancer. These modifications serve as biomarkers for the detection, prognosis, 
prediction and therapy response of bladder cancer. Epigenetic modulating drugs have 
shown promise in treating hematological malignancies like myelodysplastic syndrome and 
leukemia. Currently many of these drugs are in clinical trials also for the treatment of solid 
tumors. We have previously performed a genome-wide DNA methylation profiling in 
bladder cancer and found many genes methylated in promoter as well as in intragenic 
CpG islands (CGI). It is well documented that promoter methylation can lead to gene 
silencing, but intragenic methylation is still under investigation. To identify the effect of 
intragenic methylation on gene silencing, we selected the most hypermethylated and 
lowly expressed genes in bladder cancers and studied their reactivation pattern by treating 
bladder cancer cell lines with decitabine (DAC) and trichostatin A (TSA). For this we 
selected a set of 21 most methylated genes, nine of which were methylated in the 
promoter region, 10 in intragenic regions and in two the methylation CGI was downstream 
of the gene. First we confirmed the methylation of these genes in bladder cancer cell lines 
T24 and RT112. We treated both cell lines either with DAC or with DAC and TSA and 
investigated gene expression with q-RT-PCR.  Among eight genes which are exclusively 
methylated at intronic CGIs in the tumours, four genes NR4A2, PCDH7, TCF7L1 and GATA2 
showed similar methylation in the cell lines and were also silenced. These four genes were 
re-expressed after the treatment with DAC and TSA. This shows that gene body CpG island 
methylation can also lead to gene silencing.  
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Introduction 
DNA methylation is currently the most widely studied epigenetic aberration. DNA 
methylation is mediated by the cytosine DNA methyltransferase (DNMT) family of enzymes 
that catalyze the transfer of a methyl group from S-adenosyl methionine to DNA. DNMT1 is 
primarily responsible for maintaining the methylation signature by copying the pre-
existing methylation pattern onto the daughter strand after DNA replication. DNMT3A and 
DNMT3B are de novo enzymes that target previously unmethylated CpGs [1, 2]. Many 
studies have shown that promoter CGI methylation leads to the repression of gene 
expression [3, 4], while the effect of intragenic CGI methylation was less clear. There is 
currently more data to support the hypothesis that intragenic DNA methylation is a 
consequence of other mechanisms of transcriptional regulation, including histone 
modifications, nucleosome positioning and replication timing [5]. Interestingly, recent 
evidence suggested that variable methylation levels of individual CpG sites affect the 
binding affinity of transcription factors to nearby binding sites [6, 7]. This may offer a 
further mechanism by which specific intragenic CpG sites can affect transcription.  
Drugs that inhibit DNA methyltransferases (DNMTs) were shown to reactivate silenced 
genes and induce differentiation or apoptosis of malignant cells [8]. Currently, patients 
with myelodysplastic syndrome and leukemia are treated with DNA methylation inhibitors 
such as azacitidine and decitabine [9, 10]. Histone acetylation is associated with 
transcriptional activation, whereas conversely, deacetylation of histones is associated with 
gene silencing and transcriptional repression. HDAC inhibitors like trichostatin inhibit 
deacetylation and hence increase gene transcription. 
Bladder cancer (BCa) is the fifth most common solid neoplasm in humans [11]. About 80% 
of bladder cancers present as non-muscle invasive (NMIBC), 70% of which will recur and 
10-20% of which will eventually progress to muscle-invasive disease (MIBC) [12, 13]. A high 
number of low grade NMIBC has a mutation in the fibroblast growth factor receptor 3 
(FGFR3) oncogene [14, 15]. MIBC is associated with the inactivation of tumor suppressor 
genes like TP53 and RB1 [16-18]. Besides the genetic aberrations, alteration in the 
epigenetic landscape like DNA methylation, histone modifications and nucleosome 
remodeling are associated with neoplasms including bladder cancer [19, 20].  
In this regard we previously performed a genome-wide methylation study and found 
many genes methylated in bladder cancer [21]. Most of these genes were targets of 
polycomb repressor complexes (PcGs), which play a crucial role in the early development 
[22]. This genome-wide methylation study in bladder cancer has shown that methylation is 
equally distributed over both promoter CpG islands and gene body CpG islands. However, 
what the consequence of this intragenic methylation is regarding expression of the gene is 
unknown. Given these interesting results, we aimed to identify the effect of intragenic 
methylation on transcription in bladder cancer cell lines. Therefore we studied the 
expression of genes methylated in BCa using BCa cell lines before and after the treatment 
with epigenetic reactivating drugs DAC and Trichostatin A (TSA).  
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Materials and methods 
Bladder cancer cell lines and drug treatment 
Two bladder cancer cell lines T24 and RT112 were obtained from the American Type 
Culture Collection and cultured with standard Dulbecco’s modified eagle medium (DMEM) 
supplemented with 10% heat inactivated fetal calf serum (FCS), 25 units/ml penicillin and 
25 µg/ml of streptomycin in a humid atmosphere of 5% CO2 at 37°C. Decitabine (Sigma-
Aldrich, St Louis, MO, USA) was dissolved in dimethylsulfoxide (DMSO) as a 0.1 M stock 
solution and stored at -80˚C. Cells were seeded (3*105 cells/100 mm dish) and treated 24 h 
later with 3 µM decitabine for 72 hrs. For decitabine treatment, the medium with the drug 
was refreshed every 24 h. For the combination treatment, 0.5 µM trichostatin A (TSA, 
Calbiochem) was added in the last 12 hrs. The control group comprised cells grown under 
the same condition but treated with DMSO. After 72 hrs the cells were harvested, 
subsequently DNA and RNA were isolated for methylation detection and gene expression 
analysis by RT-PCR. We performed two independent treatments with the cell lines using 
both DAC alone and together with TSA and harvested the RNA separately for gene 
expression analysis.  
 
Nucleic acid isolation and bisulfite conversion 
DNA was extracted with the QIAamp DNA mini kit (Qiagen) according to the 
manufacturer’s recommended protocol. RNA was extracted with the RNeasy Mini-kit 
(Qiagen, Valencia, California, USA) according to the manufacturer's recommended 
protocol. The concentration and purity of RNA and DNA was measured using the 
NanoDrop ND-1000 Spectrophotometer (Thermo scientific, Wilmington, USA). Bisulfite 
conversion of genomic DNA was performed using the EZ DNA Methylation Gold Kit (Zymo, 
CA, USA) according to the manufacturer recommendations. 
 
cDNA synthesis and real time RT-PCR 
For cDNA synthesis we used the enzyme reverse transcriptase (RT), an RNA-dependent 
DNA polymerase which is isolated from a retrovirus; Moloney Murine Leukemia Virus (M-
MLV RT). The reverse transcription reaction (M-MLV Reverse Transcriptase from Invitrogen, 
Paisley, UK) was carried out as follows: a mixture of 1 µg of the isolated RNA, 1.5 µL random 
primer, 1 µL 10mM dNTP mixture (10 mM of dATP, dGTP, dCTP and dTTP each at neutral 
pH) and water to a final volume of 12 µL was incubated at 65˚C for 5 min. Then, the mixture 
containing 4 µL 5x First-Strand buffer (250 mM Tris-HCl (pH 8.3 at room temperature), 375 
mM KCl, 15 mM MgCl2), 1 μl RNaseOUT™ Recombinant Ribonuclease Inhibitor (40 units/μl) 
and 2 µL 0.1M DTT was added. This reaction mixture was incubated at 37˚C for 2 min. 
Finally, 1 μl (200 units) of M-MLV RT was added and incubated at 25˚C for 10 min followed 
by 37˚C for 50 min. The reaction was inactivated by heating at 70˚C for 15 min. Real time 
PCR was performed using 12.5 ng cDNA, 7.5 pmol of primers and 12.5 µl of SYBR Green 
Master Mix (SensiMix SYBR Hi-ROX Kit from BIOLINE). The primers used are listed in 
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Supplementary Table 1. RPLP0 gene was used as housekeeping gene to which all tested 
genes were normalized. H19 and SMPD3 genes were used as positive controls for the 
treatment with decitabine and TSA respectively. H19 is an imprinted gene and which was 
shown to be methylated in BCa cell lines and which can be re-expressed with the DAC 
treatment [23].  SMPD3 is a gene that was proven to be silenced in BCa cell lines by histone 
methylation and hypoacetylation, but not by DNA methylation and which can be re-
expressed with the TSA treatment [24].  All the reactions were performed in triplicates. The 
PCR conditions were as follows: 95°-10 min (activation of the enzyme), 95°-15 sec 
(denaturation) and 60°-1 min (annealing). Forty cycles were performed. Real time PCR was 
performed on the Applied Biosystems 7500 Real-time PCR system (Applied Biosystems, CA, 
USA). The ΔΔCt is (Normalized Ct value of the treatment and control with the house 
keeping gene, followed by subtracting the Ct value of the treatment with the control) 
calculated for all the genes investigated in the cell lines by treating with DAC and TSA. We 
calculated the fold change of re-expression using 2n, where n represents the ΔΔCt. 
 
Quantitative methylation specific PCR (Q-MSP) 
The primers selected for real-time quantitative MSP (Q-MSP) assays were designed for CpG 
dinucleotides located in the promoter and intronic regions of the selected genes using 
Methyl Primer software [25]. The primers used are listed in Supplementary Table 1. Q-MSP 
reactions were performed in the Applied Biosystems 7500 Real-time PCR system (Applied 
Biosystems, CA, USA) as follows: each reaction included 5 µl of bisulfite converted DNA 
(12.5 ng), 7.5 µl of primers (7.5 pmol), 12.5 µl of SYBR Green Master Mix. In each 96-well 
plate, multiple negative controls (DEPC treated water) were included. Bisulfite converted 
Human Universal Methylated DNA Standard (Zymo, CA, USA) was used as control. 
 
BS-SNaPshot 
We used the Bisulfite Specific Snapshot method described in [21] to investigate the 
methylation of selected genes in BCa cell lines T24 and RT112.  A list of primers and probes 
used is given in Supplementary Table 1. The method involves bisulfite conversion of 
genomic DNA (EZ DNA methylation gold kit, Zymo Research Corp, Orange, CA, USA), 
followed by subsequent amplification of interesting CGIs. The PCR products were treated 
with 2 units of Exonuclease I (ExoI) and 3 units of Shrimp Alkaline Phosphatase (SAP) (USB, 
Cleveland, Ohio USA). This was followed by a single-nucleotide probe- extension assay 
using a SNaPshot Multiplex kit (Applied Biosystems, Foster City, CA) and probes designed 
to anneal to either the forward strand or the reverse strand of a PCR product adjacent to 
the CpG site of interest. These probes were fitted with T-tails of different length at their 5’ 
ends to allow separation of the extension products by size [26]. The mutation detection 
reactions were performed in a total volume of 10 µl containing 2 µl SAP/ExoI treated PCR 
product, 2.5 µl SNaPshot Multiplex Ready Reaction mix, 1 x Big Dye sequencing buffer, and 
1 µl probe mix. Thermal cycler conditions were: 25 cycles of 10 seconds at 95˚C, 5 seconds 
at 50˚C, and 30 seconds at 60˚C. The products were treated with 1 unit SAP at 37°C for 60 
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min, and at 75°C for 15 min, and were analyzed on an automatic sequencer (ABI PRISM 
3130 XL Genetic Analyzer, Applied Biosystems) with the fluorescent label on the 
incorporated ddNTP indicating the presence or absence of a mutation. For analysis of the 
data, we used GeneMarker Software version 1.7 (SoftGenetics, State College, PA, USA). 
Methylation percentages were calculated by using the formula: Height of the C/G-peak / 
(Height of the C/G-peak + Height of the T/A peak) multiplied by 100.   
 
Results 
Methylation of intronic CGIs is associated with reduced gene expression 
Promoter methylation leads to gene silencing, while the effect of the intragenic 
methylation is still under investigation. Our earlier genome-wide study [21] in bladder 
tumours revealed no specific preference for methylation of promoter regions. Instead, 
methylation was distributed proportionally over CGIs in promoter regions, within genes 
and in intergenic regions in accordance with the number of probes present on the array in 
the respective regions (Figure 1). Twenty-six percent of the probes represented on the 
array were located in promoter regions and a similar percentage of probes were 
methylated. Likewise, 53% of the probes were located in gene bodies, and the same 
percent of probes was methylated. To investigate whether methylation outside the 
promoter regions was also associated with low or absent gene expression, we next used 
the Oncomine database to compare genes with methylated CGIs with the available 
genome-wide expression profiles of bladder cancer [27-32]. We selected 71 highly 
methylated genes to look for the expression profile. This information could be obtained for 
54 out of 71 genes. Of these 54 genes, 22 showed promoter CGI methylation, 17 (77.3%) of 
which were positively correlated with low expression. The remaining 32 genes showed 
intragenic methylation. Interestingly, 23 (72%) of these genes were also lowly expressed in 
bladder cancers (data not shown). These data suggest that not only promoter CGI 
methylation but also methylation of intronic CGIs can lead to reduced gene expression.  
 
Selection of genes to study re-expression with DAC and TSA 
We selected a set of 21 methylated CGIs from different genes, these comprised nine genes 
with promoter methylation only, 2 genes with CGIs methylated in promoter and an 
internal CGI,  8 with intragenic methylation and two that had methylation of a downstream 
CGI. Positions of the CGIs with respect to the gene i.e. promoter, inside etc. were as 
indicated by Agilent. The methylation profile of these 21 CGIs in tumors was determined 
previously [21] and is shown in Figure 2 for 8 genes (see below) with internal methylation 
and in Supplementary Figure 1 for the remaining 13. First we investigated the methylation 
of these CGIs in cell lines T24 and RT112 using the BS-SNaPshot assay. This clearly showed 
that the CGIs were also methylated in the cell lines (Table 1).  
Subsequently, we then focused on the eight genes NR4A2, MEIS1, PCDH7, VAX2, TCF7L1, 
OTX1, TBX15 and GATA2 that were exclusively methylated in the gene body in tumours 
(n=44). We analyzed the methylation of upstream and internal CGIs in these genes in more 
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detail using Q-MSP. The position of the Q-MSP primers relative to the transcriptional start 
site is indicated in Figure 2. As the Q-MSP primers cover at least 3 to 4 CpGs, this analysis 
provides a more thorough picture of methylation than the array. Results of the Q-MSP are 
depicted in Figure 3. For instance, the OTX1 gene as depicted in Figure 2 was methylated in 
tumours on the green CGI overlapping exon 4 and only low levels of methylation were 
detected in the blue CGI that covers the promoter and rst exon. Figure 3 shows that in the 
two bladder cancer cell lines two regions upstream of position -1586 relative to the 
transcription start site (TSS) are methylated as is the internal CGI (position 3258-3392), but 
not the region (-316)-(-214) that is closes to the TSS. Together these results show that 
methylation of NR4A2, PCDH7, TCF7L1 and GATA2 in the two cell lines is similar to the 
methylation prole of the tumours. Among these four genes NR4A2, PCDH7 and TCF7L1 
displayed exclusive intragenic CGI methylation, while the promoter CGIs are 
unmethylated. MEIS1 was found to be methylated to a large extent in the gene body, while 
the promoter region closes to the gene body was found methylated in the cell lines unlike 
tumours. OTX1, TBX15 and VAX2 genes were found to be methylated in the promoter and 
gene body as opposed to the methylation pattern we observed in the tumours. This is 
most probably because of the dierence in methylation pattern between the tumours and 
cell lines.  
 
 
Figure 1: DNA methylation in bladder cancer is not promoter specic, instead it is evenly distributed over the 
genome according to the probes present on the array. Positions of the probes are according to the 
annotation of Agilent. 
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Table 1: Methylation percentages of the selected genes in two bladder cancer cell lines T24 and RT112 
investigated by BS-SNaPshot. 
 Methylation % 
Gene T24 RT112 
GRIK2 81 69 
ZNF503 13 77 
HOXA7 100 100 
OSR1 93 100 
FOXA1 100 100 
SIM2 100 100 
SNRPF 72 63 
HOXA9 51 100 
NR4A2 88 100 
EVX2 53 96 
VAX2 100 100 
OTX1 100 100 
GATA2 90 90 
MEIS1 100 100 
TBX15 89 95 
ONECUT2 27 94 
TCF7L1 100 100 
PCDH7 36 96 
SIM1 91 82 
FEZF1 100 100 
BHLHB5 88 97 
 
 
Figure 2: Methylation pattern of multiple CGIs per gene as obtained from the Agilent 244K array. The gene 
and the position of its CGIs are shown above the bar graph and are based on the UCSC Genome browser 
NCBI36/hg18 assembly. Each colored bar represents an individual CpG probe of a similarly colored CGI. Data 
is shown as the average log fold change per probe for 44 tumours. Positions of the probes for the BS-
SnapShot assay (results is Table 1) are indicated with an asterisk. The positions of Q-MSP primers used in 
Figure 3 are indicated relative to the transcription start site. All 8 genes shown in this gure were exclusively 
methylated at intragenic CGIs in 44 bladder tumours.  
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Figure 3: In depth methylation analysis of CGIs of the 8 selected genes. Methylation percentage of individual 
CpG islands investigated by Q-MSP is shown for two bladder cancer cell lines T24 and RT112. Legends 
represent primer position with respect to the transcription start site (TSS, see also Figure 2), Y-axis represents 
relative methylation percentage to in-vitro methylated DNA. 
Re-expression of the genes with DAC and TSA 
To assess whether the 21 genes selected are epigenetically regulated, the two bladder 
cancer cell lines were treated with epigenetic-modulating drugs DAC and TSA. We 
performed two independent treatments with both the drugs. From each treatment, we 
isolated RNA and performed the q-RT-PCR with all the genes in triplicates. The ΔΔCt values 
after treatment with DAC and DAC plus TSA are given in Table 2 (see materials and 
methods for a detailed explanation). Also included are positive controls H19 and SMPD3. 
The RT112 cell line showed re-expression of all genes except FOXA1, SNRPF, ONECUT2, 
PCDH7 and BHLHB5. The T24 cell line showed re-expression of all genes except ZNF503, 
FOXA1, SNRPF, EVX2 and ONECUT2. The genes NR4A2, PCDH7 and TCF7L1, with gene body 
CGI methylation were re-expressed after treatment with DAC and with DAC plus TSA. 
However, PCDH7 was re-expressed only in the T24 cell line. In general we observed a 
higher re-expression when both the drugs DAC and TSA were used in combination. A 
difference in the ability to restore expression was evident among the two cell lines as 
RT112 cells re-expressed the studied genes to a higher extent compared to the T24 cell 
line. To exclude that re-expression could be due to transcription starting in the body of the 
gene we checked expression of NR4A2 and MEIS1 using multiple primer sets. There was no 
difference in expression (see Supplementary Figure 2). 
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Discussion 
We performed a genome wide study of CGI methylation in bladder cancer using a 244K 
array. Of the probes on the array about half were from intragenic CGIs and to our surprise 
we observed that the intragenic CGIs were as frequently methylated as promoter related 
CGIs. We therefore decided to investigate the effect of methylation of promoter and gene 
body CpG islands on gene expression. Comparing the methylated genes with gene 
expression profiles obtained from the public domain suggested that about 70% of the 
genes methylated at the intragenic or promoter CGIs had low transcriptional activity. After 
extensive rechecking, we identified three genes, NR4A2, PCDH7 and TCF7L1 that were 
methylated exclusively in CGIs in the gene body in bladder tumours as well as in two 
bladder cancer cell lines. We observed re-expression of these genes using RT-PCR 
following treatment of the bladder cancer cell lines with decitabine with or without 
trichostatin. By using multiple primer pairs we could exclude that this was due to 
activation of an internal transcription start site for NR4A2.  
It is generally known that gene regulation is affected by promoter methylation [3, 4].  Data 
on the effect of methylation of internal CGIs on gene expression up till now is scarce. 
However, the data so far rather suggest that methylation of internal CGIs does not affect 
gene transcription in a negative way. Some of these papers were recently reviewed by 
Shenker [5] and Jones [33]. For instance, Hellman and colleagues [34] studied X-linked 
gene silencing using an array with 49% of the probes in the intragenic coding region. They 
observed that the active X-allele displayed a higher overall as well and intragenic 
methylation than the inactive X-allele [34]. In addition, Rauch and Maunakea [35, 36] found 
that intragenic methylation was even associated with higher level of gene transcription 
and they proposed that intragenic methylation is a mechanism which regulates the use of 
alternative promoters. Aran and colleagues [37] found a link between intragenic 
methylation and replication timing and claimed that early replicating genes inclined to be 
active and show high intragenic methylation levels. Salem et al., [38] showed that the PAX6 
gene was methylated in exon 5 in bladder and colon cancer cell lines, and that this was not 
associated with the inhibition of gene expression. Smith et al., [39] found that methylation 
of non-promoter CGIs were associated with up-regulation of gene expression in colorectal 
cancer. 
In the light of these contrary results we propose two alternative explanations for our 
findings. Firstly, reactivation of genes with internal methylated CGIs could occur in trans 
through reactivation of a transcription factor gene by DAC treatment. Secondly, the 
methylated internal CGI could associate in CIS with the promoter region and negatively 
affect gene expression. 
In conclusion we show that intragenic methylation can also lead to gene silencing, which 
can be rescued using the epigenetic modulating drugs. Further studies are necessary to 
unravel the mechanism behind this. Hence it is important to study the methylation all over 
the genome, instead of focusing on promoters only.  
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Supplementary Figure 1: (previous  3  pages) Methylation pattern of multiple CGIs per gene. The gene of 
interest and the position of relevant CGIs shown above the graph were based on the UCSC Genome browser 
NCBI36/hg18 assembly. Each colored bar represents an individual CpG probe of a specic CGI. Data is shown 
as the average log fold change per probe. 
Supplementary Figure 2: Expression of NR4A2 and MEIS1 genes using multiple primer sets in T24 cell lines 
after treatment with DAC. MEIS1 A primers spanned intron 12. MEIS1 B primers spanned intron 5 and MEIS1 C 
primers spanned intron 7. NR4A2 A primers spanned intron 1 and NR4A2 B primers spanned intron 2. 
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Discussion 
6.1 Aim of the thesis 
Bladder cancer is the fifth most common cancer in the western world and comprises 
distinct histopathological forms. Studies based on genomic alterations proposed a two 
pathway model for the pathogenesis of bladder cancer. Besides genomic changes 
epigenomic alterations also play a role in bladder cancer pathogenesis. Epigenetics covers 
several changes to the genome that do not alter the DNA sequence but can be inherited 
during cell division [1]. Major examples of epigenetic modifications are methylation of CG 
dinucleotides (CpGs) in the DNA and post-translational histone modifications. The work 
described in this thesis was aimed at unraveling aberrant DNA methylation in bladder 
tumours in order to shed light on the pathogenesis of bladder tumours and to identify and 
validate biomarkers that can be used in the clinic to diagnose recurrences and predict 
progression. To this end, we performed a genome-wide methylation profiling study and 
investigated the identified changes further regarding their diagnostic and prognostic 
performance. The results will be discussed in a wider perspective, and also implications for 
future research will be made. 
 
6.2 Implications of genome-wide methylation profiling in bladder cancer  
The general implications of the genome-wide investigation will be discussed here. The 
genome-wide DNA methylation analysis revealed distinct methylation patterns in bladder 
cancer subtypes. We observed that NMIBCs with a wild-type FGFR3 gene have more 
methylated CGIs and that the intensity of methylation is more profound than in the FGFR3 
mutant NMIBC and MIBC groups. Similar results were recently described by Serizawa et al 
[2]. The difference in methylation presents additional evidence that the two subgroups of 
NMIBC develop along different pathogenesis pathways. WT NMIBCs also have more wide 
spread chromosomal aberrations than FGFR3 MT NMIBCs [3-5]. The extensive methylation 
in WT NMIBC is reminiscent of the CpG island methylator phenotype (CIMP) in colorectal 
cancers (CRC) and gliomas [6-10]. When we compared the genes representing the CIMP 
genotype in BC with the genes representing CIMP genotype in CRC and glioma, there was 
no overlap. This confirms that CGI methylation is tissue and tumour type specific [11].   
Supporting the previous reports in other solid tumors [12-17], a high proportion of the 
genes we found de novo methylated in bladder cancer are repressed by polycomb 
complexes (PcG) in embryonic stem cells. PcG target genes are as much as 12 times as 
likely to be silenced by DNA methylation in cancer as non-PcG target genes. PcG 
complexes silence genes by methylation of histone H3 at lysine 27 (H3K27). The 
association between DNA methylation and PcG has further been substantiated by the 
finding of interactions between DNMT1, DNMT3A, DNMT3B and several PcG complex 
subunits like EZH2 and BMI1 [18]. Another recent study showed that 49% of the genes 
methylated in colon cancer are polycomb targets in embryonic stem cells [19], agreeing 
with Schlesinger and colleagues who showed that genes prone to tumor specific 
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hypermethylation in colon cancer were more likely to be marked by H3K27 methylation in 
normal tissues than genes lacking H3K27 methylation [15]. In this perspective, we found 
that 56% of the hypermethylated genes in bladder cancer are PcG targets in embryonic 
stem cells. Our ndings conrm those of Wol et al, who found that 40% of the methylated 
genes in BC are PcG targets [20]. These epigenetic alterations thus may occur in early 
development specically in stem or progenitor cells and might be bladder cancer specic 
and this strengthens the further understanding of bladder cancer tumorigenesis. This 
implies that methylation is an early event in bladder cancer in accordance with Feinberg 
[21].  
We have observed that methylation is equally distributed over both promoter CpG islands 
and gene body CpG islands. It is generally known that gene regulation is aected by 
promoter methylation [22, 23].  Data on the eect of methylation of internal CGIs on gene 
expression up till now is scarce. However, the data so far rather suggest that methylation of 
internal CGIs does not aect gene transcription in a negative way. Some of these papers 
were recently reviewed by Shenker [24] and Jones [25]. For instance, Hellman and 
colleagues [26] studied X-linked gene silencing using an array with 49% of the probes in 
intragenic coding regions. They observed that the active X-allele displayed a higher overall 
as well and intragenic methylation than the inactive X-allele [26]. In addition, Rauch and 
Maunakea [27, 28] found that intragenic methylation was even associated with higher level 
of gene transcription and they proposed that intragenic methylation is a mechanism 
which regulates the use of alternative promoters. Aran and colleagues [29] found a link 
between intragenic methylation and replication timing and claimed that early replicating 
genes inclined to be active and show high intragenic methylation levels. Salem et al., [30] 
showed that the PAX6 gene was methylated in exon 5 in bladder and colon cancer cell 
lines, and that this was not associated with the inhibition of gene expression. Smith et al., 
[31] found that methylation of non-promoter CGIs were associated with up-regulation of 
gene expression in colorectal cancer. 
In our study, besides promoter methylation, we found more than 50% of all methylated 
CpG dinucleotides to be located in CGIs within gene bodies. Given these intriguing results, 
we investigated the association of promoter and intragenic methylation on gene 
expression by treating BC cell lines with epigenetic reactivating drugs like DAC and TSA. 
We observed that intragenic CGI methylation was associated with low gene expression to 
a similar extent as was observed for promoter methylation, suggesting that gene silencing 
may be the result of both promoter and internal CGI methylation. We observed that it was 
possible to restore the gene expression with the epigenetic modulating drugs in BC cell 
lines, also for the genes that harbored internal methylated CGIs. In the light of these results 
we propose two alternative explanations for our ndings. Firstly, reactivation of genes with 
internal methylated CGIs could occur in trans through reactivation of a transcription factor 
gene by DAC treatment. Secondly, the methylated internal CGI could associate in CIS with 
the promoter region and negatively aect gene expression. This suggests that intragenic 
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methylation also contributes to gene silencing. However, additional experiments are 
necessary to unravel the underlying mechanisms. 
6.3 Distinct DNA methylation patterns exist in bladder cancer and are valuable 
prognostic indicators 
One of the major goals of this work was to identify and validate methylated CGIs that could 
serve as biomarkers for the prediction of disease course. In the genome wide study we 
discovered several markers that were associated with disease course. The subsequent 
validation on a custom array resulted in the identication of four genes whose CGIs were 
associated with progression to MIBC in pTa tumors when the CGIs were methylated.  
pTa tumours represent about 60% of all primary bladder tumours. Progression to MIBC in 
pTa tumours is much lower than for pT1 tumours, however, the risk is still 10% and 60-70% 
of patients will have on average 3 recurrences, warranting long-term surveillance [32-34]. 
We found that methylation of the TBX2, TBX3, GATA2 and ZIC4 genes was signicantly 
associated with progression. These genes encode transcription factors that are important 
in lineage decisions during development [35]. Gene expression proling studies showed 
that all these genes are more expressed in NMIBC than in MIBC [36], which ts with our 
ndings as we observed that these genes are more methylated in MIBC. TBX2 and TBX3 are 
transcriptional repressors that inhibit expression of the ARF gene a.o., thereby nally 
inhibiting P53 activation [37]. This may present an alternative for mutation of P53, which is 
frequent in MIBC. Recently, Reinert et al., showed methylation of the TBX4 gene associated 
with progression in pTa tumours, this suggests the important role of T-box genes in BC 
progression [38]. Mutations that reduce DNA binding of GATA2 were discovered in familial 
myelodysplastic syndrome [39]. Currently, prediction of progression in NMIBC is based on 
the progression scores developed by Sylvester [34], that have been taken up in the EAU 
guidelines. These scores are based on the clinicopathological factors. The markers 
described in this work enhanced the predictive accuracy of these risk scores by 23% and 
could thus contribute to a further objective stratication of patients.  
6.4 Surveillance of NMIBC using markers based on tumour-specic DNA methylation 
One of the major issues in the treatment of NMIBC patients is the high recurrence rate; 
therefore the surveillance of the patients is a major clinical challenge. Can we nd 
molecular biomarkers based on DNA methylation for the surveillance of these patients, 
which can provide an alternative for the current invasive cystoscopy? The development of 
sensitive, non-invasive tests for diagnosis and surveillance has been performed in the last 
decade with not much success. Current FDA approved urine tests BTA stat, BTA TRAK, 
UroVysion, and Quanticyt have shown good sensitivity and specicity for low grade 
NMIBC, but failed to present similar results in the following studies [40-42]. Therefore these 
markers are not used yet in routine clinical practice. Currently, the cystoscopy and cytology 
on voided urine are very important predictors of recurrence at the rst follow-up, three 
months after trans-urethral resection of the bladder tumour (TURBT) [43]. While cystoscopy 
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is an invasive procedure, cytology has a low median sensitivity of 35% in detecting low 
grade NMIBC [42].  
Epigenetic modifications, especially DNA methylation showed promise in developing urine 
based biomarkers in BC. However, previous studies were mainly performed on primary 
tumors and were not aimed at the detection of recurrent bladder tumors and therefore the 
sensitivities reported might be too high. This is very important as most of the recurrences 
are small with low stage and grade. An ideal test for the surveillance of BC that can replace 
the cystoscopy should be urine based, sensitive, cost-effective, easy to perform with 
limited material, and with no interobserver variability.  
The genome-wide screening and subsequent independent validation allowed us to 
confirm 110 CGIs that significantly differed in methylation in tumours when compared to 
urine-derived DNA from age-matched non-bladder cancer controls. These CGIs 
represented potential biomarkers for urine tests. Urine-based tests are especially 
important for surveillance of patients with NMIBC after transurethral resection in order to 
provide an alternative for cystoscopy, which is an invasive diagnostic method.  
To identify recurrence specific DNA methylation markers especially for low and 
intermediate risk group patients, we selected 8 candidate CGIs from our genome-wide 
study and tested their performance in two independent sets of recurrence-associated 
urines along with urines from non-bladder cancer controls. This enabled us to identify a 
three marker combination (OTX1, ONECUT2 and OSR1) together with FGFR3 mutation assay 
detecting recurrent BC in voided urine with a sensitivity of 79% at a specificity of 90%. At 
least 21% of the recurrent tumours were undetected with our test. This could be because 
of the absence of tumour cells in the corresponding urine, which can be improved by 
collecting and testing multiple urines from the patient. So far this is only the second study 
which investigated methylation biomarkers for the exclusive detection of recurrent BC in 
voided urine. The study by Zuiverloon [44] et al., reported a four gene methylation panel to 
detect recurrent bladder tumours with a sensitivity of 72% at a low specificity of 55%.  
We also observed that multiple tumours from a patient are highly concordant in their 
methylation percentage, which emphasize the value of the markers. This is very crucial for 
a recurrent diagnostic assay. Unlike the FGFR3 mutation, methylation seems to be 
consistent in the primary and recurrent tumours. 
Most of the times urine DNA is very limited, therefore it is challenging to perform many 
individual molecular tests on the limited amount of the DNA. To overcome this, we 
developed a sensitive and quantitative multiplex methylation assay, which require as low 
as 30 to 40 ng DNA unlike other assays. Moreover, we have shown that they are highly 
reproducible between different operators. Combined material costs of the two assays, 
including DNA isolation, amount to about 30€. Personnel costs depend on the number of 
assayed samples, being cheaper when many samples are analyzed simultaneously. The 
sensitivity of our assay combination is similar to the sensitivity of the current gold standard 
white light cystoscopy with sensitivity in the range of 68 to 83% when compared to the 
more sensitive blue light cystoscopy [45, 46]. Given the comparable sensitivities of urine 
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testing and cystoscopy, we postulate that patients under surveillance for recurrent BC in 
the low/intermediate risk groups could benefit from urine testing and only followed by 
cystoscopy when the urine test is positive. 
 
6.5 Future perspectives 
Our genome-wide study provided an insight into the methylation profiles of different 
subtypes of BC and identified novel biomarkers for the detection, surveillance and 
prognosis of BC. The possible CIMP phenotype we observed in NMI-FGFR3 WT tumours 
should be further validated to find the CIMP signature. This could help in finding 
methylation markers specific for the NMI FGFR3 wild type tumours. It is also interesting to 
study the polycomb target genes methylated in BC further. These epigenetic alterations 
occurring in early development specifically in stem or progenitor cells might be bladder 
cancer specific and this strengthens the further understanding of bladder cancer 
tumorigenesis in future. 
The diagnostic and prognostic markers developed in this study showed very good 
sensitivities and specificities. Therefore, more multicenter validation studies should be 
initiated to take these markers a step closer to the clinical utilization. We are currently 
undertaking the validation of the urine biomarkers in a longitudinal prospective study. The 
prospective studies should also be performed to compare the markers with current gold 
standard methods. For example, the urine diagnostic markers should be compared with 
cystoscopy in a randomized trial to see if the urine markers can replace the cystoscopy and 
when. As we discussed in chapter 4, especially for the low and intermediate risk NMIBC 
surveillance, urine markers could be tested initially and a cystoscopy can be performed if 
the urine test is positive. This will help reducing the unnecessary cystoscopies for this 
group of low risk patients. Furthermore, other work has shown that recurrent tumours are 
often detected earlier than with cystoscopy and this is called the anticipatory effect. In 
addition, more recurrences are detected when the urologist who performs the cystoscopy 
is aware of a positive urine test result [47]. The other problem with the urine methylation 
markers is the low sensitivity, which mostly occurs because of the absence of tumour cells 
in that particular urine. As with the FGFR3 assay, we should investigate if testing of multiple 
urines can improve the detection rate [48, 49]. An increase in analytical sensitivity of the 
FGFR3 and the methylation assay can be further expected with the use of next generation 
sequencing in the future.  
The prognostic markers for pTa tumours that we discovered performed better that the 
clinicopathological parameters combined in the EAU guidelines. The current TNM grading 
system is not perfect as it suffers from interobserver variability. Currently, the prognostic 
markers are being further validated in an independent large set of tumours. Previously, we 
developed a molecular grading system (mG 1.0) based on the presence/absence of an 
FGFR3 mutation and expression of the proliferation marker Ki-67. This molecular grading 
system was superior to the EAU scores [32, 50]. The disadvantage of this mG is the fact that 
immunohistochemistry (IHC) is required to score the Ki-67 marker. IHC is cumbersome and 
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not entirely reproducible. We therefore aim to combine the methylation profile with the 
FGFR3 mutation status to come to an mG 2.0 system that is better than mG 1.0 and more 
reproducible. 
It is also important to study the intragenic methylation and its effect on gene transcription 
further.  
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Summary
Bladder cancer is the 5th most common cancer and the 9th leading cause of cancer death
with an estimated 386,300 new cases and 150,200 deaths in the year 2008 worldwide. The
majority of bladder cancers occur in men, with a male: female ratio of 3:1. The incidence is
about 20 new cases per year per 100,000 people in the U.S. Smoking is the most consistent
and common 3 times risk factor associated with bladder cancer. Most bladder tumours
(75%) are non-muscle invasive (i.e. pTa-pT1) at first presentation. There are two major
problems in the management of these patients. First, NMIBC characterized by a high risk of
recurrence (55-85%), with most recurrences in the first year after trans-urethral resection
(TUR). These recurrences are detected by cystoscopy, considered as the gold standard,
which is performed every 3-4 months depending on the clinicopathological features. This
is often in combination with urine cytology. After a two-year recurrence free period, the
intensity of follow up may be lowered. Cystoscopy and cytology are routinely used in
clinical practice. However, cystoscopy is invasive, inconvenient for the patients and costly,
while cytology has low sensitivity for low grade tumours. Hence, it is necessary to develop
urine based non-invasive and sensitive diagnostic tools for the detection of recurrent
bladder cancer.
The second major concern is to prevent progression (10-15%) to muscle invasive bladder
cancer. The ability to distinguish NMI tumors with invasive capacity from those not likely to
become invasive would be of great clinical benefit. At this moment this prediction is based
on clinicopathological factors. However, individual prediction of prognosis by clinical and
pathological features is still very tricky and can suffer from interobserver variability. NMIBC
patients with high chance of progression might be better treated with radical cystectomy
in an early stage of the disease. Therefore it is necessary to develop more accurate
predictors for progression, which helps in stratification of patients for follow-up and
treatment.
Over the past decade it has become clear that cancer is an epigenetic as well as a genetic
disease. Epigenetic modifications can act as surrogate markers for diagnosis and prognosis
of cancer. Methylation of cytosine bases in DNA is an important epigenetic mechanism and
the analysis of aberrant DNA methylation in bodily fluids has the potential to substantially
improve cancer screening, detection and prognosis. Therefore, epigenetic markers may aid
in solving the two major clinical problems summarized above. If these markers prove to
have added value over the established clinico-pathological variables, they could become
part of the clinical practice. This thesis deals with the development of molecular epigenetic
biomarkers as tools for the management of bladder cancer patients. To achieve this we
performed genome-wide methylation screening, followed by identification and validation
of urine markers for recurrence detection as well as tissue biomarkers for predicting
progression in NMIBC.
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In chapter 2, a systematic review on DNA methylation based biomarkers identified so far 
for the diagnosis and prognosis of bladder cancer is presented. Chapter 3 describes the 
results of genome-wide methylation study. The genome-wide screening and subsequent 
validation allowed us to identify and validate 110 CpG islands that significantly differed in 
methylation in tumours when compared to urine-derived DNA from age-matched non-BC 
controls. These CGIs represent potential biomarkers for urine tests. Furthermore, four 
markers (TBX2, TBX3, GATA2 and ZIC4) for predicting progression were identified and 
validated in pTa tumours. The predictive accuracy of EORTC risk scores for progression, 
which are based on clinicopathological factors are improved by 23% by adding 
methylation of TBX2, TBX3, and GATA2 to the model. Therefore these molecular markers 
will add to the prediction scores and will aid in improving the predictive accuracy, thereby 
helping in patient stratification.
An ideal test for surveillance of BC that can replace cystoscopy should be urine based, 
sensitive, cost-effective, easy to perform with limited material, and with no inter observer 
variability. To achieve this, we developed a 3-plex assay for the diagnosis of recurrent BC. 
Our three gene methylation panel consisting of OTX1, ONECUT2 and OSR1 achieved a 
sensitivity of 74% with a specificity of 90% for the detection of recurrent bladder tumors in 
voided urine. Previously, we showed an inverse correlation between FGFR3 mutation and 
methylation, therefore we combined the 3-plex methylation assay with the FGFR3 
mutation assay. The combination of both assays increased sensitivity of detection to 79%. 
This assay needs as low as 35 ng of DNA, hence there will be sufficient DNA in most urine 
samples to perform these assays.  Both assays are easy to perform in a standard molecular 
diagnostic laboratory. Moreover, we have shown that they are highly reproducible 
between different operators. Combined material costs of the two assays, including DNA 
isolation, amount to about 30€. Personnel costs depend on the number of assayed 
samples, being cheaper when many samples are analyzed simultaneously. We further 
observed that multiple tumours from a patient have highly concordant methylation of the 
3 markers, which underlines the usefulness of the markers for surveillance. The sensitivity 
of our assay combination is similar to the sensitivity of the current gold standard white 
light cystoscopy with sensitivity in the range of 68 to 83% when compared to the more 
sensitive blue light cystoscopy. Given the comparable sensitivities of urine testing and 
cystoscopy, we postulate that patients under surveillance for recurrent BC in the 
low/intermediate risk groups could benefit from urine testing and only followed by 
cystoscopy when the urine test is positive. This is described in chapter 4. The genome-
wide study in bladder cancer revealed that methylation is distributed equally in the 
promoter and intragenic regions. Promoter methylation is proved to be inversely 
correlated with gene expression, while intragenic methylation is still under investigation. 
In chapter 5, we addressed the effect of intragenic methylation on transcription using 
bladder cancer cell lines. The results indicated that, intragenic methylation can also lead to 
gene silencing and the expression was able to be restored by treating the cell lines with 
the epigenetic modulating drugs. We propose two alternative explanations for our
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findings. Firstly, reactivation of genes with internal methylated CGIs could occur in trans 
through reactivation of a transcription factor gene by DAC treatment. Secondly, the 
methylated internal CGI could associate in cis with the promoter region and negatively 
affect gene expression. Further studies are necessary to unravel the mechanism behind 
this. Hence it is important to study the methylation all over the genome, instead of 
focusing on promoters only.
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Samenvatting
Blaaskanker is één van de meest voorkomende vormen van kanker. Per jaar wordt deze
ziekte bij ongeveer 386.300 mensen geconstateerd. Zo’n 150.200 mensen overlijden
jaarlijks aan deze ziekte.  De ziekte komt vaker voor bij mannen dan bij vrouwen, in een
verhouding van ongeveer 3:1. De incidentie in de Verenigde Staten is ongeveer 20 nieuwe
patiënten per jaar per 100.000 mensen. Roken is de meest duidelijke en bekende
risicofactor geassocieerd met blaaskanker en verhoogt het risico ongeveer drie maal.
De meeste blaastumoren (75%) zijn bij presentatie niet-spierinvasief (NMIBC, pTa-pT1). De
behandeling van deze tumoren gaat gepaard met twee lastige problemen. Ten eerste
wordt NMIBC gekarakteriseerd door een hoog risico op recidieven (55-85%), vooral in het
eerste jaar na een transurethrale resectie (TUR). Deze recidieven worden opgespoord met
behulp van cystoscopie, een methode die, afhankelijk van de klinische en pathologische
gegevens, elke 3 tot 4 maanden wordt herhaald. Cystoscopie wordt op dit moment
beschouwd als de Gouden Standaard. Naast cystoscopie wordt ook vaak cytologie
uitgevoerd op urine. Als na een periode van twee jaar geen recidieven zijn opgetreden,
wordt de frequentie van de onderzoeken verminderd. Alhoewel cystoscopie en cytologie
routinematig worden toegepast, zitten aan beide methoden toch wat nadelen:
cystoscopie is een invasieve techniek die flink wat ongemak met zich meebrengt, en
cytologie is niet zo’n gevoelige techniek om NMIBC tumoren op te sporen. Daarom is het
noodzakelijk om onderzoek te verrichten naar de mogelijkheid voor niet-invasieve testen
die met een grote gevoeligheid recidief tumoren opsporen.
Het tweede lastige probleem is het feit dat zo’n 10-15% van de NMIBC tumoren 
uiteindelijk toch spierinvasief wordt. Een test die kan aantonen welke patiënten het 
meeste risico lopen op zo’n spierinvasieve tumor zou zeer welkom zijn. Patiënten met een 
hoog risico zouden misschien een betere prognose hebben na radicale cystectomie. Op dit 
moment wordt deze voorspelling gebaseerd op klinisch-pathologische parameters. Dit 
kan echter nog onderhevig zijn aan interobserver variatie. Daarom is het van belang om 
meer accurate voorspellers te ontwikkelen, die kunnen helpen om de patiënten te 
stratificeren voor behandeling.
De laatste jaren is duidelijk geworden dat epigenetische veranderingen, naast genetische 
ook een belangrijke rol spelen in het ontstaan van kanker. Epigenetische veranderingen 
kunnen worden gebruikt als surrogaatmerkers voor diagnose en prognose van kanker. 
Methylering van cytosinebasen in DNA is een belangrijk epigenetisch mechanisme en het 
aantonen van afwijkende DNA-methylering in lichaamsvloeistoffen kan in hoge mate 
bijdragen aan het verbeteren van het (vroeg) opsporen van kanker, de diagnose en de 
prognose. Als deze merkers toegevoegde waarde blijken te hebben bovenop de al 
bestaande methoden, zouden ze kunnen worden ingepast in de standaard klinische 
praktijk. Dit proefschrift beschrijft de ontwikkeling van moleculaire epigenetische merkers 
als instrumenten om de behandeling van blaaskankerpatiënten te sturen. Om dit te
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bereiken hebben we een genoombrede methylatiescreening uitgevoerd om merkers te 
identificeren. Deze merkers zijn gevalideerd voor het gebruik als urinegebaseerde test 
voor detectie van recidieven en het voorspellen van progressie naar spierinvasieve ziekte. 
In hoofdstuk 2 wordt een systematisch overzicht gegeven van op DNA-methylatie 
gebaseerde biomerkers die tot nu toe zijn geïdentificeerd voor de diagnose en prognose 
van blaaskanker. Hoofdstuk 3 beschrijft de resultaten van een genoombrede 
methylatiestudie. Deze genoombrede screening en de daarop volgende validatie stelde 
ons in staat om 110 CpG eilanden te identificeren en te valideren waarvan de methylatie in 
tumoren aanzienlijk verschilde van die in DNA geïsoleerd uit urine van controlepersonen 
zonder blaaskanker van dezelfde leeftijd. Deze CGI's vertegenwoordigen potentiële 
biomerkers voor urinetesten. Verder werden vier merkers geïdentificeerd (TBX2, TBX3, 
GATA2 en ZIC4) met voorspellende waarde voor progressie en deze zijn gevalideerd in pTa 
tumoren. Door toevoeging van methylering van TBX2, TBX3 en GATA2 aan het model voor 
de EORTC risicoscores voor progressie, die gebaseerd zijn op klinische en pathologische 
factoren, nam de voorspellende waarde toe met 23%. Daarom zal toevoeging van deze 
moleculaire merkers aan de risicoscores helpen bij het verbeteren van de predictieve 
nauwkeurigheid en aldus bijdragen aan de patiëntenzorg.
Een ideale test voor het volgen van patiënten met blaaskanker, die cystoscopie kan 
vervangen, moet niet-invasief zijn, gevoelig, goedkoop, eenvoudig uit te voeren met een 
beperkte hoeveelheid patiëntenmateriaal, en zonder inter-observer variabiliteit. Hiervoor 
hebben we een 3-plex assay ontwikkeld voor de diagnose van recidief blaastumoren. Het 
genmethylatiepanel van de drie genen OTX1, ONECUT2 en OSR1 bereikt een gevoeligheid 
van 74% met een specificiteit van 90% voor de detectie van recidieftumoren in urine. 
Eerder toonden we een omgekeerde correlatie aan tussen FGFR3 mutatie en methylering, 
daarom hebben we de 3-plex methylatie assay gecombineerd met de FGFR3 mutatie assay. 
De combinatie van beide assays verhoogde de detectiegevoeligheid tot 79%. Deze test is 
uit te voeren met een minimale hoeveelheid DNA van 35 ng, waardoor er voldoende DNA 
in de meeste urinemonsters aanwezig was om deze assays uit te voeren. Beide testen zijn 
gemakkelijk uit te voeren in een standaard moleculair diagnostisch laboratorium. 
Bovendien hebben we aangetoond dat de test zeer reproduceerbaar is tussen 
verschillende uitvoerders. Gecombineerde materiaalkosten van de twee assays, inclusief 
DNA-isolatie, bedraagt ongeveer €30. De personeelskosten zijn afhankelijk van het aantal 
geteste monsters en worden lager wanneer veel monsters gelijktijdig geanalyseerd 
worden. We hebben verder vastgesteld dat meerdere tumoren van een patiënt een zeer 
vergelijkbaar methylatieprofiel van de 3 merkers hebben, wat de bruikbaarheid van de test 
voor recidieftumoren onderstreept. De gevoeligheid van de methylatietest gecombineerd 
met FGFR3 mutatie-analyse is vergelijkbaar met de gevoeligheid van de huidige gouden 
standaard, cystoscopie met wit licht, welke een gevoeligheid heeft tussen de 68 tot 83%
vergeleken met de meer gevoelige cystoscopie met blauw licht. Gezien de vergelijkbare 
gevoeligheden van urinetesten en cystoscopie, nemen we aan dat patiënten onder 
controle voor recidieftumoren in de lage/intermediaire risicogroepen zouden kunnen
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profiteren van urinetesten en alleen een cystoscopie hoeven te ondergaan als de urinetest 
positief is. Dit wordt beschreven in hoofdstuk 4. Tijdens de genoombrede studie bij 
blaaskanker bleek dat methylatie gelijkmatig verdeeld is in de promotor en intragene 
regio's. Promotormethylering is omgekeerd evenredig met genexpressie, terwijl het effect 
van intragene methylatie nog onduidelijk is. In hoofdstuk 5 onderzochten we het effect 
van intragene methylatie op transcriptie met behulp van blaaskankercellijnen. De 
resultaten gaven aan dat intragene methylering ook kan leiden tot gene silencing en dat 
de expressie kon worden hersteld door behandeling van de cellijnen met drugs die 
methylering beïnvloeden. Er zijn twee mogelijke verklaringen voor onze bevindingen. Ten 
eerste kan reactivering van genen met intern gemethyleerde CGI plaatsvinden in trans 
door reactivering van een transcriptiefactorgen door DAC behandeling. Anderzijds zou de 
gemethyleerde interne CGI in cis met de promotor regio kunnen associëren en zo een 
negatieve invloed hebben op genexpressie. Verdere studies zijn nodig om het 
mechanisme hierachter te ontrafelen. Daarom is het belangrijk om de methylering van het 
hele genoom te bestuderen, in plaats van het onderzoek te beperken tot genpromoters.
Chapter 7
144
Acknowledgements
Well, where to start?! It’s been an exciting journey towards my PhD since I came to
Germany in October 2005 to pursue my master’s degree. I joined Erasmus MC in 2008 and
so many people have helped me throughout this very challenging period of my life. I
would like to take this opportunity to express my deep and sincere gratitude to all of you.
Firstly, I would like to thank Professor Juergen Bode for his supervision during my master
degree in Germany. I thank you for all your support and also for recommending that I join
Erasmus MC. Thank you for accepting our invitation to be in the panel of my PhD defence.
I would like to express my sincere gratitude to the reading committee: Dr. Els Berns, Dr.
Arno van Leenders and Prof. Chris Bangma. It was a great honour to have you in my
reading committee. I appreciate the time and energy you invested in reading my thesis
and accepting it. Els - I will always remember our AACR conference in Chicago. It was an
enjoyable experience with you and your team.
I really don’t have the words to express my gratitude to Ellen. Firstly, thank you so much
Ellen for giving me the opportunity to do a PhD in your lab and to be a part of this very
interesting project. You were always so approachable and always there to share my
professional and personal life. You supported me all the way during my PhD with your
scientific expertise. I always enjoyed our weekly meetings and discussion of ideas. You
always encouraged me in the most difficult times and gave me the strength and
confidence to succeed. I have learned so much from you personally and professionally and
you will remain my most admirable professor. You also supported me to quit my contract
early and to take up the new job in London. I know it was a very difficult decision to make
for both of us as I hadn’t even started writing my thesis by that time. However, I have put
all my efforts in finishing the writing and you have been very swift in editing my thesis. I
still remember the last day of my work when you had to read and recommend changes for
the last chapters. I couldn’t have finished writing my thesis early to join my new job
without your precious time and support. I enjoyed the freedom you gave me in planning
and prioritising my work. You have always given me the opportunity to present my work in
national and international meetings, which has helped me so much. Finally, I feel very
lucky to get an opportunity to work with you and Erasmus MC. Ellen, you never said no to
anything I asked for and I will surely miss working with you. I wish you lots of success for
your future.
Dear Angela, I feel fortunate to have you as my co-promoter. You are the best supervisor.
You always had great ideas and criticisms. You are very friendly and approachable. I still
remember my early days when I was new and trying to settle down and you were always
Appendices
145
there to comfort me. I had the longest association with you during my PhD and sitting
beside you was the best thing. Thank you for your extensive support in professional and
personal life. You were always there to share my good and bad times. More than a
supervisor, you are a friend and a great colleague to work with. I have learnt so much from
you and I couldn’t have done all this alone without your guidance. I wish you all the very
best for your future career. What a coincidence, we both are now working on
gynaecological cancers and I hope we will continue to work together in the future. I had a
great time with you during so many meetings, especially during the AACR in Orlando.
Thank you so much for reading my thesis and giving your comments to make it better.
Thanks for reading all those Dutch letters and yeah Roy took over in the end. Angela, thank
you so much for your help with the Dutch summary.
Roy, you have joined me in the most dicult times of my PhD. Well, since you joined it all
started to work. So you are my lucky mascot. I can’t think of a more brilliant student. We
both worked so much together in the last two years of my PhD. You are so adept with
Microsoft oce and Photoshop. I hope I will be able to do things like you sometime in my
life. I have learned so much from you in formatting and designing reports. Without you I
couldn’t have nished writing my thesis in such a short time. I thank you from the bottom
of my heart for helping me with the gures and the design of my thesis. I am very lucky to
had a student like you. I wish you all the success with your master studies. I also would like
to thank my students Shirmey, Merel and Naveed from the bottom of my heart for
contributing to my project. I wish you all a very good future ahead.
Hedy, you rock. I always enjoyed your company. I could always have a good discussion 
with you about the work and my personal life. You always had so much patience in 
explaining things and exchanging ideas. I cherish your company. Since you joined I had 
the opportunity to explore!! I mean all the parties and fun we had together was great. I wish 
you all the luck in the future. Hedy thanks for proof reading my thesis.
Lucie, thank you so much for contributing to my work. You always had patience to provide
the samples and data. I will always cherish all the good times we had together. Thanks for
your support all the way. I hope you soon nish your PhD and have a fruitful career
thereafter. Hedy and Lucie thanks for being my paranymphs.
Willi and Tahlita thanks for providing the patient data whenever I needed it. It was always
fun working with you. I wish you both a great career ahead.
Marcel, it was great sharing the work place with you. I always enjoyed your presence. You
always had a big story for everything!!! Thanks for repairing my bike whenever I needed. I
wish you a great time ahead in your life.
Chapter 7
146
Irene and Kirsten thanks for all your support in ordering things and helping in the lab. It
was great working with you. I wish you both a great career ahead.
Magda, you taught me so many things in the lab. I still remember those initial days and
you are a great teacher. You always had brilliant ideas. Your help with my house moving
was unforgettable. I wish you a fruitful career ahead.
Stephen, Cheno, Aleksander, Miriam, Martijn, Ricardo, Amiet, Silvia and Priscilla: you all
were great. It was great working with you all and my best wishes for your future career.
I would like to express my sincere gratitude to all my PhD colleagues especially Riaz, Ashok,
Vaibhav, Noorie, Bert-Jaap, Marcia, Marijn, Yaser and Ines for all the good times we shared.
I also want to thank all my lab mates and colleagues from the department of pathology.
I also would like to thank my friends Kayal, Edward, Lisette, Serah, Riaz and Tanjal for all the 
support especially when Siri was born. I will never forget the love and affection we all 
shared.
I want to thank my dearest friends Laddu and Sopna for being with me all the way through
my life and you deserve a part of this success. Mahi thanks for your support bro.
Finally, special thanks to my parents, wife and sisters for your unconditional love and I am
sure I couldn’t have achieved this without your support. I lovingly dedicate this thesis to
you all. Big thanks to my wife for all the love, support and affection in the most difficult
phases of my PhD.
I want to apologise for the people whom I have forgotten. Last, but not the least, I want to
thank my new colleagues in London, especially Martin, Allie, Jackie, Jane, Kate and Shahzia
for your support in preparing for my defence.
Appendices
147
Curriculum Vitae
Raju Kandimalla was born on April 21st 1980 in Warangal, AP, India. He studied Bachelor 
and Master of Science in Biochemistry at Kakatiya University, Warangal, India from 1998- 
2003. After getting his Master’s degree, he worked for two years from 2003-2005 in Aristo 
Pharmaceuticals ltd, Hyderabad, India. In 2006 he moved to Germany and earned his 
International Master’s degree in Biochemistry. He did his Master’s thesis at Helmholtz 
Centre for Infection Research, Braunschweig, Germany under Prof.dr. Juergen Bode, which 
was funded by Cellca GmbH. In 2008 he moved to the Netherlands to start his PhD project 
under the guidance of Prof.dr. E.C. Zwarthoff in the Department of Pathology, Erasmus MC, 
Rotterdam. This project is funded by Erasmus MC, MRACE grant 2007, European 
Community Seventh Framework program FP7/2007-2012, grant agreement no 201663, 
and Dutch Cancer Society grant no. EMCR 2007-3863. The aims of his PhD project were to 
perform genome-wide DNA methylation profiling in bladder cancer to find novel 
biomarkers for the diagnosis and prognosis of bladder cancer patients. The results 
obtained during these four and half years effected in four publications, which are 
presented in this thesis. He also guided two master and two bachelor students for their 
internships. He also presented the work described in this thesis in the form of posters and 
presentations at several national and international meetings. These include the annual 
meeting of American Association of Cancer Research (2011-2012), EMBL Conference on 
Omics and Personalized Health held in Heidelberg, Germany (2012), European Association 
of Urology meeting held in Paris, France (2012), European Meeting on Molecular 
Diagnostics held in the Hague (2011), European Workshop on Cytogenetics and Molecular 
Genetics of Solid Tumors, Radboud University Nijmegen Medical Centre, Nijmegen (2010), 
KWF Tumor Cell Biology Meeting, Lunteren (2009), MGC PhD student symposium and 
workshop held in Leiden and  Brugge (2011 and 2009), GROW PhD Course Epigenetics, 
Maastricht University Medical Center, Maastricht (2008) and the Molecular Medicine Day 
(2009-2012). In 2012 he received the prize for best poster at the European Association of 
Urology (EAU) meeting held in Paris. He is presently working as a post doctoral fellow at 
the Institute for Women's Health, University College London under Prof.dr. Martin 
Widschwendter.
Chapter 7
148
PhD Portfolio
Name PhD student: Raju Kandimalla
Erasmus MC Department: Pathology
Research School: Molecular Medicine
PhD period: Jan 2008 - Sep 2012
Promotor: Prof. dr. E.C. Zwarthoff 
Co-Promotor: Dr. A.G. van Tilborg
1. PhD training
Year ECTS
Courses and workshops
Workshop on Bioinformatic Analysis, Tools and Services 2008 0.2
Course Molecular Diagnostics III 2008 0.3
Course Analysis of microarray gene expression data 2008 1.0
Course Molecular Medicine 2008 1.9
Course Classical Methods for Data analysis 2008 5.7
2nd GROW PhD Course Epigenetics, Maastricht UMC 2008 5.0
Basic Course on ‘R´ 2010 1.0
Biomedical English writing and communication 2010 4.0
Course on Photoshop and Illustrator CS5 2011 0.3
Next Generation Sequencing Training 2011 0.3
Workshop on InDesign CS5 2012 0.2
Oral presentations
2nd GROW PhD Course Epigenetics, Maastricht UMC 2008 0.3
Annual presentations scientific meetings at the JNI 2009-2011 0.9
16th MGC PhD student workshop, Bruges, Belgium 2009 0.3
KWF Tumor Cell Biology Meeting, Lunteren, the Netherlands 2009 0.3
12th European Workshop on Cytogenetics and Molecular Genetics of
Solid Tumors, UMC St. Radboud, Nijmegen 2010 0.3
21st MGC PhD Symposium, LUMC, Leiden 2011 0.3
7th European Meeting on Molecular Diagnostics, The Hague 2011 0.3
EMBL Conference Omics and Personalized Health, Heidelberg, Germany 2012 0.3
16th Molecular Medicine Day, Erasmus MC, Rotterdam 2012 0.3
Course Basic and Translational Oncology of the Erasmus MC Post
Graduate School 2012 0.3
Appendices
149
Poster presentations Year ECTS
Molecular Medicine Day, Erasmus MC, Rotterdam 2009-2011 0.9
AACR Annual Meeting, Orlando, FL, USA 2011 0.3
27th Annual EAU Congress, Paris, France 2012 0.3
AACR Annual Meeting, Chicago, IL, USA 2012 0.3
International conferences
AACR Annual Meeting, Orlando, FL, USA 2011 1.0
27th Annual EAU Congress, Paris, France 2012 1.0
AACR Annual Meeting, Chicago, IL, USA 2012 1.0
EMBL Conference Omics and Personalized Health, Heidelberg, Germany 2012 1.0
Department meetings
Weekly JNI scientific meetings 2008-2012 2.5
Monthly JNI oncology lectures 2009-2012 1.0
Work group discussions 2008-2012 2.5
2. Teaching activities
Supervision of master student internship (January-September) 2010 8.0
Supervision of bachelor student internship (March-September) 2010 8.0
Supervision of master student internship (March-August) 2011 8.0
Supervision of bachelor student internship (Nov 2010-August 2011) 2011 8.0
Lovingly dedicated to my parents

 CH3
CH3
C
G
C
G
G
C
Raju Kandimalla
Genome-Wide DNA Methylation Proling in Bladder cancer 
and Identication of Diagnostic and Prognostic Markers
Genom
e-W
ide DN
A M
ethylation Proling in Bladder cancer and Identication of Diagnostic and Prognostic M
arkers     -     Raju Kandim
alla
Invitation
for the public defense of
the PhD thesis
Genome-Wide DNA Methylation 
Profiling in Bladder cancer and 
Identification of Diagnostic and 
Prognostic Markers
Raju Kandimalla
On December 12th, 2012
at 15:30
Location: 
Professor Andries Queridozaal
Erasmus MC Faculteit
Eg-370
Rotterdam
Paranymphs:
Hedy Vekony
h.vekony@erasmusmc.nl
&
Lucie Kompier
l.kompier@erasmusmc.nl
